<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">99341</article-id><article-id pub-id-type="doi">10.7554/eLife.99341</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.99341.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Evolutionary Biology</subject></subj-group></article-categories><title-group><article-title>Characterization of cancer-driving nucleotides (CDNs) across genes, cancer types, and patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lingjie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6506-4457</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Tong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Liufu</surname><given-names>Zhongqi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiangnyu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5078-8906</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Shijie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xueyu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Changhao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Bingjie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Zheng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1552-0060</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Qichun</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Chenli</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Mengfeng</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tracy</surname><given-names>Miles E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Xuemei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6044-6002</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wu</surname><given-names>Chung-I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7263-4238</contrib-id><email>ciwu@uchicago.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wen</surname><given-names>Hai-Jun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8676-1254</contrib-id><email>wenhj5@mail.sysu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0064kty71</institution-id><institution>State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/034t30j35</institution-id><institution>Center for Excellence in Animal Evolution and Genetics, The Chinese Academy of Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00zat6v61</institution-id><institution>GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/034t30j35</institution-id><institution>CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Shenzhen</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02xe5ns62</institution-id><institution>Cancer Center, Clifford Hospital, Jinan University</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01vjw4z39</institution-id><institution>Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024mw5h28</institution-id><institution>Department of Ecology and Evolution, University of Chicago</institution></institution-wrap><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Weigel</surname><given-names>Detlef</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0243gzr89</institution-id><institution>Max Planck Institute for Biology Tübingen</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Weigel</surname><given-names>Detlef</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0243gzr89</institution-id><institution>Max Planck Institute for Biology Tübingen</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>17</day><month>12</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP99341</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-05-29"><day>29</day><month>05</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-06-02"><day>02</day><month>06</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.05.29.596367"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-09-04"><day>04</day><month>09</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.99341.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-10-25"><day>25</day><month>10</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.99341.2"/></event></pub-history><permissions><copyright-statement>© 2024, Zhang et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Zhang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-99341-v1.pdf"/><related-article related-article-type="article-reference" ext-link-type="doi" xlink:href="10.7554/elife.99340" id="ra1"/><abstract><p>A central goal of cancer genomics is to identify, in each patient, all the cancer-driving mutations. Among them, point mutations are referred to as cancer-driving nucleotides (CDNs), which recur in cancers. The companion study shows that the probability of <italic>i</italic> recurrent hits in <bold>n</bold> patients would decrease exponentially with <italic>i</italic>; hence, any mutation with <italic>i</italic> ≥ 3 hits in The Cancer Genome Atlas (TCGA) database is a high-probability CDN. This study characterizes the 50–150 CDNs identifiable for each cancer type of TCGA (while anticipating 10 times more undiscovered ones) as follows: (i) CDNs tend to code for amino acids of divergent chemical properties. (ii) At the genic level, far more CDNs (more than fivefold) fall on noncanonical than canonical cancer-driving genes (CDGs). Most undiscovered CDNs are expected to be on unknown CDGs. (iii) CDNs tend to be more widely shared among cancer types than canonical CDGs, mainly because of the higher resolution at the nucleotide than the whole-gene level. (iv) Most important, among the 50–100 coding region mutations carried by a cancer patient, 5–8 CDNs are expected but only 0–2 CDNs have been identified at present. This low level of identification has hampered functional test and gene-targeted therapy. We show that, by expanding the sample size to 10<sup>5</sup>, most CDNs can be identified. Full CDN identification will then facilitate the design of patient-specific targeting against multiple CDN-harboring genes.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cancer evolution</kwd><kwd>cancer drivers</kwd><kwd>targeted therapy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32150006</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Chung-I</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100015956</institution-id><institution>Guangdong Key R&amp;D Project of China</institution></institution-wrap></funding-source><award-id>2022B1111030001</award-id><principal-award-recipient><name><surname>Wen</surname><given-names>Hai-Jun</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32293193</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Chung-I</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32293190</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Chung-I</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82341092</award-id><principal-award-recipient><name><surname>Wen</surname><given-names>Hai-Jun</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012166</institution-id><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source><award-id>2021YFC0863300</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Chung-I</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012166</institution-id><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source><award-id>2021YFC0863400</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Chung-I</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32200493</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Chung-I</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32370659</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Chung-I</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100021171</institution-id><institution>Guangdong Basic and Applied Basic Research Foundation</institution></institution-wrap></funding-source><award-id>2023A1515010016</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Chung-I</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Analyses of discovered cancer-driving nucleotides (CDNs) reveal their evolutionary, biochemical, and therapeutic characteristics that are often shared among multiple cancer types.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Tumorigenesis in each patient is driven by mutations in the patient’s genome. Hence, a central goal of cancer genomics is to identify <italic>all</italic> driving mutations in each patient. This task is particularly challenging because each driving mutation is present in only a small fraction of patients. As the number of driver mutations in each patient has been estimated to be &gt;5 (<xref ref-type="bibr" rid="bib3">Armitage and Doll, 1954</xref>; <xref ref-type="bibr" rid="bib8">Bozic et al., 2010</xref>; <xref ref-type="bibr" rid="bib23">Hanahan and Weinberg, 2011</xref>; <xref ref-type="bibr" rid="bib6">Belikov, 2017</xref>; <xref ref-type="bibr" rid="bib1">Anandakrishnan et al., 2019</xref>), the total number of driver mutations summed over all patients must be quite high.</p><p>This study, together with the companion paper (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>), is based on one simple premise: in the massively repeated evolution of cancers, any advantageous cancer-driving mutation should recur frequently, say, <italic>i</italic> times in <bold>n</bold> patients. The converse that nonrecurrent mutations are not advantageous is part of the same premise. We focus on point mutations, referred to as cancer-driving nucleotides (CDNs), and formulate the maximum of <italic>i</italic> (denoted <italic>i<sup>*</sup></italic>) in <bold>n</bold> patients if mutations are not advantageous. For example, in The Cancer Genome Atlas (TCGA) database with <bold>n</bold> generally in the range of 500–1000, <italic>i<sup>*</sup></italic> = 3. Hence, any point mutation with <italic>i</italic> ≥ 3 is a CDN. At present, a CDN would have a prevalence of 0.3% among cancer patients. If the sample size approaches 10<sup>6</sup>, a CDN only needs to be prevalent at 5 × 10<sup>–5</sup>, the theoretical limit (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>).</p><p>Although there are many other driver mutations (e.g., fusion genes, chromosomal aberrations, epigenetic changes, etc.), CDNs should be sufficiently numerous and quantifiable to lead to innovations in functional tests and treatment strategies. Given the current sample sizes of various databases (<xref ref-type="bibr" rid="bib11">Cerami et al., 2012</xref>; <xref ref-type="bibr" rid="bib59">Weinstein et al., 2013</xref>; <xref ref-type="bibr" rid="bib53">Tate et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">de Bruijn et al., 2023</xref>), each cancer type has yielded 50–150 CDNs while the CDNs to be discovered should be at least 10 times more numerous. The number of CDNs currently observed in each patient is 0–2 for most cancer types. This low level of discovery has limited functional studies and hampered treatment strategies.</p><p>While we are proposing the scale-up of sample size to discover most CDNs, we now characterize CDNs that have been discovered. The main issues are the distributions of CDNs among genes, across cancer types, and, most important, among patients. In this context, cancer driver genes (CDGs) would be a generic term. We shall use ‘canonical CDGs’ (or conventional CDGs) for the driver genes in the union set of three commonly used lists (<xref ref-type="bibr" rid="bib5">Bailey et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Sondka et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Martínez-Jiménez et al., 2020</xref>). In parallel, CDN-harboring genes, referred to as ‘CDN genes’, constitute a new and expanded class of CDGs.</p><p>The first issue is that CDNs are not evenly distributed among genes. The canonical cancer drivers such as <italic>TP53</italic>, <italic>KRAS,</italic> and <italic>EGFR</italic> tend to have many CDNs. However, the majority of CDNs, especially those yet-to-be-identified ones, may be rather evenly distributed with each gene harboring only 1–2 CDNs. Hence, the number of genes with tumorigenic potential may be far larger than realized so far. The second issue is the distribution of CDNs and CDGs among cancer types. It is generally understood that the canonical CDGs are not widely shared among cancer types. However, much (but not all) of the presumed cancer-type specificity may be due to low statistical resolution at the genic level.</p><p>The third issue concerns the distribution of CDNs among patients. Clearly, the CDN load of a patient is crucial in diagnosis and treatment. However, the conventional diagnosis at the gene level may have two potential problems. One is that many CDNs do not fall in canonical CDGs as signals from one or two CDNs get diluted. Second, a canonical CDG, when mutated, may be mutated at a non-CDN site. In those patients, the said CDG does not drive tumorigenesis. We shall clarify the relationships between CDN mutations and genes that may or may not harbor them.</p><p>The characterizations of discovered CDNs are informative and offer a road map for expanding the CDN list. A complete CDN list for each cancer type will be most useful in functional test, diagnosis, and treatment. A full list of mutations that drive the evolution of complex traits is at the center of evolutionary genetics. Such phenomena as complex human diseases (e.g., diabetes) (<xref ref-type="bibr" rid="bib56">Vujkovic et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">Lagou et al., 2023</xref>; <xref ref-type="bibr" rid="bib64">Xue et al., 2023</xref>; <xref ref-type="bibr" rid="bib50">Suzuki et al., 2024</xref>), the genetics of speciation (<xref ref-type="bibr" rid="bib15">Chen et al., 2022b</xref>; <xref ref-type="bibr" rid="bib58">Wang et al., 2022</xref>; <xref ref-type="bibr" rid="bib62">Wu, 2022</xref>), and the evolution of viruses in epidemics (<xref ref-type="bibr" rid="bib20">Deng et al., 2022</xref>; <xref ref-type="bibr" rid="bib45">Ruan et al., 2022</xref>; <xref ref-type="bibr" rid="bib10">Cao et al., 2023</xref>; <xref ref-type="bibr" rid="bib46">Ruan et al., 2023</xref>) are all prime examples in need of a full list. Thanks to their massively repeated evolution, cancers could be the first complex systems well resolved at the genic level.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>In molecular evolution, a gene under positive selection is recognized by its elevated evolutionary rate (<xref ref-type="fig" rid="fig1">Figure 1A and C</xref>). There have been numerous methods for determining the extent of rate elevation (<xref ref-type="bibr" rid="bib29">Li et al., 1985</xref>; <xref ref-type="bibr" rid="bib37">Nei and Gojobori, 1986</xref>; <xref ref-type="bibr" rid="bib65">Yang and Swanson, 2002</xref>; <xref ref-type="bibr" rid="bib28">Lawrence et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">Martincorena et al., 2017</xref>; <xref ref-type="bibr" rid="bib40">Pan et al., 2022</xref>; <xref ref-type="bibr" rid="bib47">Sherman et al., 2022</xref>; <xref ref-type="bibr" rid="bib58">Wang et al., 2022</xref>; <xref ref-type="bibr" rid="bib46">Ruan et al., 2023</xref>), and cancer evolution studies have adopted many of them. However, no model has been developed to take advantage of the massively repeated evolution of cancers (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), which happens in tens of millions of people at any time.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Mutations in organismal evolution vs. cancer evolution.</title><p>(<bold>A, B</bold>) A hypothetical example of DNA sequence evolution in organism vs. in cancer with the same number of mutations. (<bold>C</bold>) Mutation distribution in two species in the organismal evolution of (<bold>A</bold>). (<bold>D, E</bold>) Mutation distribution in cancer evolution among 10 sequences may have D and E patterns. (<bold>F</bold>) Another pattern of mutation distribution in cancer evolution with a recurrent site but shows too few total mutations. Mutations of (<bold>F</bold>) are cancer-driving nucleotides (CDNs) missed in the conventional screens.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99341-fig1-v1.tif"/></fig><p>In the whole-gene analysis, <xref ref-type="fig" rid="fig1">Figure 1C–E</xref> are identical, each with <italic>A:S</italic> = 10:1, where <italic>A</italic> and <italic>S</italic> denote nonsynonymous and synonymous mutations, respectively. However, the presence of a four-hit site in <xref ref-type="fig" rid="fig1">Figure 1E</xref> is far less likely to be neutral than <xref ref-type="fig" rid="fig1">Figure 1C and D</xref>. Although the ratio in <xref ref-type="fig" rid="fig1">Figure 1F</xref><italic>, A:S</italic> = 4:1, is statistically indistinguishable from the neutral ratio of about 2.5:1, <xref ref-type="fig" rid="fig1">Figure 1F</xref> in fact has much more power to reject the neutral ratio than <xref ref-type="fig" rid="fig1">Figure 1C and D</xref>. After all, the probability that multiple hits are at the same site in a big genome is obviously very small.</p><sec id="s2-1"><title>The analyses of CDNs across the whole genome</title><p>For the entire coding regions in the cancer genome data, we define <bold><italic>A<sub>i</sub></italic></bold> (or <bold><italic>S<sub>i</sub></italic></bold>) as the number of nonsynonymous (or synonymous) sites that harbor a mutation with <italic>i</italic> recurrences. <xref ref-type="table" rid="table1">Table 1</xref> presents the distribution of <bold><italic>A<sub>i</sub></italic></bold> and <bold><italic>S<sub>i</sub></italic></bold> across the 12 cancer types with <bold>n</bold> &gt; 300 (<xref ref-type="bibr" rid="bib59">Weinstein et al., 2013</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Mutation recurrences (<bold><italic>A<sub>i</sub></italic></bold>s and <bold><italic>S<sub>i</sub></italic></bold>s) in 12 cancer types.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Lung</th><th align="left" valign="bottom">Breast</th><th align="left" valign="bottom">Central nervous system</th><th align="left" valign="bottom">Kidney</th><th align="left" valign="bottom">Upper aerodigestive tract</th><th align="left" valign="bottom">Colon</th><th align="left" valign="bottom">Endometrium</th><th align="left" valign="bottom">Prostate</th><th align="left" valign="bottom">Stomach</th><th align="left" valign="bottom">Urinary tract</th><th align="left" valign="bottom">Ovary</th><th align="left" valign="bottom">Liver</th><th align="left" valign="bottom">Average</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic><bold>Patients #</bold></italic></td><td align="left" valign="bottom"><italic><bold>1035</bold></italic></td><td align="left" valign="bottom"><italic><bold>963</bold></italic></td><td align="left" valign="bottom"><italic><bold>873</bold></italic></td><td align="left" valign="bottom"><italic><bold>711</bold></italic></td><td align="left" valign="bottom"><italic><bold>688</bold></italic></td><td align="left" valign="bottom"><italic><bold>571</bold></italic></td><td align="left" valign="bottom"><italic><bold>465</bold></italic></td><td align="left" valign="bottom"><italic><bold>465</bold></italic></td><td align="left" valign="bottom"><italic><bold>423</bold></italic></td><td align="left" valign="bottom"><italic><bold>404</bold></italic></td><td align="left" valign="bottom"><italic><bold>404</bold></italic></td><td align="left" valign="bottom"><italic><bold>367</bold></italic></td><td style="background-color: #E6E6E6;"><italic><bold>614</bold></italic></td></tr><tr><td align="left" valign="bottom"><xref ref-type="table-fn" rid="table1fn1">*</xref><italic><bold>A</bold><sub><bold>0</bold></sub></italic></td><td align="left" valign="bottom">22,540,623</td><td align="left" valign="bottom">21,683,136</td><td align="left" valign="bottom">20,783,835</td><td align="left" valign="bottom">22,247,653</td><td align="left" valign="bottom">21,580,444</td><td align="left" valign="bottom">20,601,026</td><td align="left" valign="bottom">20,766,001</td><td align="left" valign="bottom">21,300,810</td><td align="left" valign="bottom">20,892,755</td><td align="left" valign="bottom">21628918</td><td align="left" valign="bottom">22278124</td><td align="left" valign="bottom">22618059</td><td style="background-color: #E6E6E6;">21576782</td></tr><tr><td align="left" valign="bottom"><xref ref-type="table-fn" rid="table1fn1">*</xref><italic><bold>S</bold><sub><bold>0</bold></sub></italic></td><td align="left" valign="bottom">78,042,81</td><td align="left" valign="bottom">9,388,418</td><td align="left" valign="bottom">10,298,911</td><td align="left" valign="bottom">87,814,83</td><td align="left" valign="bottom">93,332,83</td><td align="left" valign="bottom">10,428,913</td><td align="left" valign="bottom">10,375,596</td><td align="left" valign="bottom">97,543,31</td><td align="left" valign="bottom">10,243,634</td><td align="left" valign="bottom">9426888</td><td align="left" valign="bottom">8746002</td><td align="left" valign="bottom">8255268</td><td style="background-color: #E6E6E6;">9403084</td></tr><tr><td align="left" valign="bottom"><italic><bold>A/S_0</bold></italic></td><td align="left" valign="bottom"><italic>2.89</italic></td><td align="left" valign="bottom"><italic>2.31</italic></td><td align="left" valign="bottom"><italic>2.02</italic></td><td align="left" valign="bottom"><italic>2.53</italic></td><td align="left" valign="bottom"><italic>2.31</italic></td><td align="left" valign="bottom"><italic>1.98</italic></td><td align="left" valign="bottom"><italic>2.00</italic></td><td align="left" valign="bottom"><italic>2.18</italic></td><td align="left" valign="bottom"><italic>2.04</italic></td><td align="left" valign="bottom"><italic>2.29</italic></td><td align="left" valign="bottom"><italic>2.55</italic></td><td align="left" valign="bottom"><italic>2.74</italic></td><td style="background-color: #E6E6E6;"><italic>2.29</italic></td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>1</bold></sub></italic></td><td align="left" valign="bottom">195958</td><td align="left" valign="bottom">44696</td><td align="left" valign="bottom">25122</td><td align="left" valign="bottom">25669</td><td align="left" valign="bottom">66924</td><td align="left" valign="bottom">94634</td><td align="left" valign="bottom">78870</td><td align="left" valign="bottom">9583</td><td align="left" valign="bottom">78834</td><td align="left" valign="bottom">66153</td><td align="left" valign="bottom">21138</td><td align="left" valign="bottom">25731</td><td style="background-color: #E6E6E6;">61109</td></tr><tr><td align="left" valign="bottom"><italic><bold>S</bold><sub><bold>1</bold></sub></italic></td><td align="left" valign="bottom">69393</td><td align="left" valign="bottom">16732</td><td align="left" valign="bottom">10182</td><td align="left" valign="bottom">9317</td><td align="left" valign="bottom">26151</td><td align="left" valign="bottom">38606</td><td align="left" valign="bottom">31982</td><td align="left" valign="bottom">3613</td><td align="left" valign="bottom">32538</td><td align="left" valign="bottom">26546</td><td align="left" valign="bottom">7227</td><td align="left" valign="bottom">9398</td><td style="background-color: #E6E6E6;">23474</td></tr><tr><td align="left" valign="bottom"><italic><bold>A/S_1</bold></italic></td><td align="left" valign="bottom"><italic>2.82</italic></td><td align="left" valign="bottom"><italic>2.67</italic></td><td align="left" valign="bottom"><italic>2.47</italic></td><td align="left" valign="bottom"><italic>2.76</italic></td><td align="left" valign="bottom"><italic>2.56</italic></td><td align="left" valign="bottom"><italic>2.45</italic></td><td align="left" valign="bottom"><italic>2.47</italic></td><td align="left" valign="bottom"><italic>2.65</italic></td><td align="left" valign="bottom"><italic>2.42</italic></td><td align="left" valign="bottom"><italic>2.49</italic></td><td align="left" valign="bottom"><italic>2.92</italic></td><td align="left" valign="bottom"><italic>2.74</italic></td><td style="background-color: #E6E6E6;"><italic>2.60</italic></td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>2</bold></sub></italic></td><td align="left" valign="bottom">2946</td><td align="left" valign="bottom">233</td><td align="left" valign="bottom">287</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">489</td><td align="left" valign="bottom">1662</td><td align="left" valign="bottom">1052</td><td align="left" valign="bottom">29</td><td align="left" valign="bottom">1176</td><td align="left" valign="bottom">816</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">46</td><td style="background-color: #E6E6E6;">737</td></tr><tr><td align="left" valign="bottom"><italic><bold>S</bold><sub><bold>2</bold></sub></italic></td><td align="left" valign="bottom">969</td><td align="left" valign="bottom">62</td><td align="left" valign="bottom">75</td><td align="left" valign="bottom">11</td><td align="left" valign="bottom">159</td><td align="left" valign="bottom">736</td><td align="left" valign="bottom">386</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">489</td><td align="left" valign="bottom">308</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">12</td><td style="background-color: #E6E6E6;">249</td></tr><tr><td align="left" valign="bottom"><italic><bold>A/S_2</bold></italic></td><td align="left" valign="bottom"><italic>3.04</italic></td><td align="left" valign="bottom"><italic>3.76</italic></td><td align="left" valign="bottom"><italic>3.83</italic></td><td align="left" valign="bottom"><italic>5.09</italic></td><td align="left" valign="bottom"><italic>3.08</italic></td><td align="left" valign="bottom"><italic>2.26</italic></td><td align="left" valign="bottom"><italic>2.73</italic></td><td align="left" valign="bottom"><italic>3.22</italic></td><td align="left" valign="bottom"><italic>2.40</italic></td><td align="left" valign="bottom"><italic>2.65</italic></td><td align="left" valign="bottom"><italic>5.67</italic></td><td align="left" valign="bottom"><italic>3.83</italic></td><td style="background-color: #E6E6E6;"><italic>2.74</italic></td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>3</bold></sub></italic></td><td align="left" valign="bottom">99</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">42</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">28</td><td align="left" valign="bottom">91</td><td align="left" valign="bottom">52</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">79</td><td align="left" valign="bottom">60</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">9</td><td style="background-color: #E6E6E6;">42.3</td></tr><tr><td align="left" valign="bottom"><italic><bold>S</bold><sub><bold>3</bold></sub></italic></td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">28</td><td align="left" valign="bottom">11</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td style="background-color: #E6E6E6;">8.08</td></tr><tr><td align="left" valign="bottom"><italic><bold>A/S_3</bold></italic></td><td align="left" valign="bottom"><italic>4.71</italic></td><td align="left" valign="bottom"><italic>9</italic></td><td align="left" valign="bottom"><italic>7</italic></td><td align="left" valign="bottom"><italic>14</italic></td><td align="left" valign="bottom"><italic>5.6</italic></td><td align="left" valign="bottom"><italic>3.25</italic></td><td align="left" valign="bottom"><italic>4.73</italic></td><td align="left" valign="bottom"><italic>6:0</italic></td><td align="left" valign="bottom"><italic>5.64</italic></td><td align="left" valign="bottom"><italic>6.67</italic></td><td align="left" valign="bottom"><italic>9:0</italic></td><td align="left" valign="bottom"><italic>9:0</italic></td><td style="background-color: #E6E6E6;"><italic>5.23</italic></td></tr><tr><td style="background-color: #90CAF9;"><sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup><bold><italic>A</italic></bold><sub><bold><italic>i ≥3</italic></bold></sub></td><td style="background-color: #90CAF9;"><bold>178</bold></td><td style="background-color: #90CAF9;"><bold>51</bold></td><td style="background-color: #90CAF9;"><bold>84</bold></td><td style="background-color: #90CAF9;"><bold>18</bold></td><td style="background-color: #90CAF9;"><bold>77</bold></td><td style="background-color: #90CAF9;"><bold>148</bold></td><td style="background-color: #90CAF9;"><bold>142</bold></td><td style="background-color: #90CAF9;"><bold>14</bold></td><td style="background-color: #90CAF9;"><bold>124</bold></td><td style="background-color: #90CAF9;"><bold>100</bold></td><td style="background-color: #90CAF9;"><bold>26</bold></td><td style="background-color: #90CAF9;"><bold>23</bold></td><td style="background-color: #90CAF9;"><bold>82.1</bold></td></tr><tr><td style="background-color: #90CAF9;"><sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup><italic><bold>A</bold><sub><bold>i ≥4</bold></sub></italic></td><td style="background-color: #90CAF9;"><bold>79</bold></td><td style="background-color: #90CAF9;"><bold>33</bold></td><td style="background-color: #90CAF9;"><bold>42</bold></td><td style="background-color: #90CAF9;"><bold>4</bold></td><td style="background-color: #90CAF9;"><bold>49</bold></td><td style="background-color: #90CAF9;"><bold>57</bold></td><td style="background-color: #90CAF9;"><bold>90</bold></td><td style="background-color: #90CAF9;"><bold>8</bold></td><td style="background-color: #90CAF9;"><bold>45</bold></td><td style="background-color: #90CAF9;"><bold>40</bold></td><td style="background-color: #90CAF9;"><bold>17</bold></td><td style="background-color: #90CAF9;"><bold>14</bold></td><td style="background-color: #90CAF9;"><bold>39.8</bold></td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>4</bold></sub></italic></td><td align="left" valign="bottom">23</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">8</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">23</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">23</td><td align="left" valign="bottom">11</td><td align="left" valign="bottom">4</td><td align="left" valign="bottom">3</td><td style="background-color: #E6E6E6;">11.1</td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>5</bold></sub></italic></td><td align="left" valign="bottom">16</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">20</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">5</td><td style="background-color: #E6E6E6;">8.2</td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>6-9</bold></sub></italic></td><td align="left" valign="bottom">27</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">13</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">32</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">7</td><td align="left" valign="bottom">12</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">2</td><td style="background-color: #E6E6E6;">10.8</td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>[10, 20)</bold></sub></italic></td><td align="left" valign="bottom">7</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">11</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">4</td><td align="left" valign="bottom">4</td><td style="background-color: #E6E6E6;">5.75</td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>≥20</bold></sub></italic></td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">4</td><td align="left" valign="bottom">4</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">8</td><td align="left" valign="bottom">8</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td style="background-color: #E6E6E6;">3</td></tr><tr><td align="left" valign="bottom"><xref ref-type="table-fn" rid="table1fn3"><sup>‡</sup></xref>Total</td><td align="left" valign="bottom">202828</td><td align="left" valign="bottom">45669</td><td align="left" valign="bottom">26596</td><td align="left" valign="bottom">25841</td><td align="left" valign="bottom">68387</td><td align="left" valign="bottom">98931</td><td align="left" valign="bottom">81898</td><td align="left" valign="bottom">9706</td><td align="left" valign="bottom">81678</td><td align="left" valign="bottom">68297</td><td align="left" valign="bottom">21387</td><td align="left" valign="bottom">25944</td><td style="background-color: #E6E6E6;">63097</td></tr><tr><td align="left" valign="bottom"><bold>SiteNbr</bold></td><td align="left" valign="bottom">22739705</td><td align="left" valign="bottom">21728116</td><td align="left" valign="bottom">20809328</td><td align="left" valign="bottom">22273396</td><td align="left" valign="bottom">21647934</td><td align="left" valign="bottom">20697470</td><td align="left" valign="bottom">20846065</td><td align="left" valign="bottom">21310436</td><td align="left" valign="bottom">20972889</td><td align="left" valign="bottom">21695987</td><td align="left" valign="bottom">22299339</td><td align="left" valign="bottom">22643859</td><td style="background-color: #E6E6E6;">21638710</td></tr><tr><td align="left" valign="bottom"><bold>nE(u)</bold></td><td align="left" valign="bottom">9.07E-03</td><td align="left" valign="bottom">1.79E-03</td><td align="left" valign="bottom">1.00E-03</td><td align="left" valign="bottom">1.06E-03</td><td align="left" valign="bottom">2.83E-03</td><td align="left" valign="bottom">3.84E-03</td><td align="left" valign="bottom">3.15E-03</td><td align="left" valign="bottom">3.72E-04</td><td align="left" valign="bottom">3.27E-03</td><td align="left" valign="bottom">2.88E-03</td><td align="left" valign="bottom">8.28E-04</td><td align="left" valign="bottom">1.14E-03</td><td style="background-color: #E6E6E6;">2.6E-03</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>See ‘Methods’ for the calculations of <bold><italic>A<sub>0</sub></italic></bold> and <bold><italic>S<sub>0</sub></italic></bold>.</p></fn><fn id="table1fn2"><label>†</label><p><bold><italic>A<sub>i</sub></italic></bold> and <bold><italic>S<sub>i</sub></italic></bold> are as defined in the text.</p></fn><fn id="table1fn3"><label>‡</label><p>‘Total’ represents the total number of missense mutations, or . ‘Site number’ refers to the count of missense sites. <bold>nE(u)</bold> is calculated based on synonymous mutations, representing the expected number of neutral mutations per site in a population of size <bold>n</bold>.</p></fn></table-wrap-foot></table-wrap><p>For neutral mutations, we define <italic>i<sup>*</sup></italic> as the threshold above which the expected numbers of <bold><italic>A<sub>i</sub></italic></bold> would be &lt;1, that is, <inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mo>≥</mml:mo><mml:msup><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mrow><mml:mo mathvariant="bold">∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, The corollary is that all <inline-formula><mml:math id="inf2"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mo>≥</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">*</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:math></inline-formula> sites are advantageous CDNs. (Since <bold><italic>S<sub>i</sub></italic></bold> is ~<bold><italic>A<sub>i</sub></italic></bold>/2.3, the same <italic>i<sup>*</sup></italic> would apply to <bold><italic>S<sub>i</sub></italic></bold> as well: <inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">S</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mo>≥</mml:mo><mml:msup><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mrow><mml:mo mathvariant="bold">∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>.) As <italic>i<sup>*</sup></italic> is a function of the number of patients (<bold>n</bold>), it is shown mathematically in the companion study (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>) that <italic>i<sup>*</sup></italic> = 3 for <bold>n</bold> &lt; 1000. Interestingly, while the <inline-formula><mml:math id="inf4"><mml:mi>E</mml:mi><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mo>≥</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></inline-formula> is &lt; 1, the expected <inline-formula><mml:math id="inf5"><mml:mi>E</mml:mi><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mo>≥</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></inline-formula> is ≪ 1, in the order of 0.001. Hence, <italic>i<sup>*</sup></italic> = 4 may be considered unnecessarily stringent.</p><p>We should note that this study is constrained by <bold>n</bold> &lt; 1000 in TCGA databases. (Databases with larger <bold>n</bold>s are also used where the actual <bold>n</bold>s are often uncertain.) At <italic>i<sup>*</sup></italic> = 3, we could detect only a fraction (&lt;10%; see below) of CDNs. Many more tumorigenic mutations may be found in the <italic>i</italic> = 1 or 2 classes although not every one of them is a CDN. Since these two classes of mutations are far more numerous, they should account for the bulk of CDNs to be discovered. Indeed, <xref ref-type="table" rid="table1">Table 1</xref> shows 76 <inline-formula><mml:math id="inf6"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mo>≥</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> CDN mutations per cancer type but 681 <bold><italic>A<sub>2</sub></italic></bold> and 56,648 <bold><italic>A<sub>1</sub></italic></bold> mutations in the lower recurrence groups. If <bold>n</bold> reaches 10<sup>5–6</sup>, most of the undiscovered CDNs in the <bold><italic>A<sub>1</sub></italic></bold> and <bold><italic>A<sub>2</sub></italic></bold> classes should be identified (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>).</p><p>In <xref ref-type="table" rid="table2">Table 2</xref>, we estimate the proportion of the <bold><italic>A<sub>1</sub></italic></bold> and <bold><italic>A<sub>2</sub></italic></bold> mutations that are possible CDNs. The relationships of <bold><italic>A<sub>3</sub></italic></bold>/<bold><italic>S<sub>3</sub></italic></bold> &gt; <bold><italic>A<sub>2</sub></italic></bold>/<bold><italic>S<sub>2</sub></italic></bold>, <bold><italic>A<sub>2</sub></italic></bold>/<bold><italic>S<sub>2</sub></italic></bold> &gt; <bold><italic>A<sub>1</sub></italic></bold>/<bold><italic>S<sub>1</sub></italic></bold>, and <bold><italic>A<sub>1</sub></italic></bold>/<bold><italic>S<sub>1</sub></italic></bold> &gt; <bold><italic>A<sub>0</sub></italic></bold>/<bold><italic>S<sub>0</sub></italic></bold> are almost always observed in <xref ref-type="table" rid="table1">Table 1</xref> with 32 <italic>(3 × 8 + 2 × 4)</italic> out of 36 such relationships. The use of <bold><italic>A</italic>/<italic>S</italic></bold> ratios may still underestimate the selective advantages of <bold><italic>A<sub>1~3</sub></italic></bold> mutations because <bold><italic>S<sub>1~3</sub></italic></bold> may have slight advantages as well (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>). Assuming <bold><italic>S<sub>1</sub></italic></bold> is truly neutral, we use <bold><italic>S<sub>0</sub></italic></bold> to <bold><italic>S<sub>1</sub></italic></bold> as the basis to calculate the excess of <bold><italic>A<sub>1~3</sub></italic></bold> in <xref ref-type="table" rid="table2">Table 2</xref> where 35 of the 36 <italic>Obs</italic>(<bold><italic>A<sub>i</sub></italic></bold>) &gt; <italic>Exp</italic>(<bold><italic>A<sub>i</sub></italic></bold>) relationships can be observed. The implication is that hundreds and, likely low thousands, of <bold><italic>A<sub>1</sub></italic></bold>s and <bold><italic>A<sub>2</sub></italic></bold>' should be CDNs, whereas we have only confidently identified ~76 strong CDNs, on average, for a cancer type. (Note that <bold><italic>A<sub>1</sub></italic></bold> excesses are less reliable since a 1% error in the calculation would mean 566 CDNs.)</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Excess of <bold><italic>A<sub>i</sub></italic></bold>s of each <italic>i</italic> class.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Recurrences</th><th align="left" valign="bottom">Lung</th><th align="left" valign="bottom">Breast</th><th align="left" valign="bottom">Central nervous system</th><th align="left" valign="bottom">Kidney</th><th align="left" valign="bottom">Upper aerodigestive tract</th><th align="left" valign="bottom">Colon</th><th align="left" valign="bottom">Endometrium</th><th align="left" valign="bottom">Prostate</th><th align="left" valign="bottom">Stomach</th><th align="left" valign="bottom">Urinary tract</th><th align="left" valign="bottom">Ovary</th><th align="left" valign="bottom">Liver</th></tr></thead><tbody><tr><td align="left" valign="bottom"><xref ref-type="table-fn" rid="table2fn1">*</xref><italic><bold>A</bold><sub><bold>1</bold></sub></italic><bold>_o</bold></td><td align="left" valign="bottom">195958</td><td align="left" valign="bottom">44696</td><td align="left" valign="bottom">25122</td><td align="left" valign="bottom">25669</td><td align="left" valign="bottom">66924</td><td align="left" valign="bottom">94634</td><td align="left" valign="bottom">78870</td><td align="left" valign="bottom">9583</td><td align="left" valign="bottom">78834</td><td align="left" valign="bottom">66153</td><td align="left" valign="bottom">21138</td><td align="left" valign="bottom">25731</td></tr><tr><td align="left" valign="bottom"><xref ref-type="table-fn" rid="table2fn1">*</xref><sup>, <xref ref-type="table-fn" rid="table2fn2">†</xref></sup><italic><bold>A</bold><sub><bold>1</bold></sub></italic><bold>_e</bold></td><td align="left" valign="bottom">198627</td><td align="left" valign="bottom">38586</td><td align="left" valign="bottom">20532</td><td align="left" valign="bottom">23582</td><td align="left" valign="bottom">60316</td><td align="left" valign="bottom">76049</td><td align="left" valign="bottom">63860</td><td align="left" valign="bottom">7888</td><td align="left" valign="bottom">66194</td><td align="left" valign="bottom">60751</td><td align="left" valign="bottom">18396</td><td align="left" valign="bottom">25720</td></tr><tr><td style="background-color: #90CAF9;"><bold>Excess</bold></td><td style="background-color: #90CAF9;">–2669</td><td style="background-color: #90CAF9;">6110</td><td style="background-color: #90CAF9;">4590</td><td style="background-color: #90CAF9;">2087</td><td style="background-color: #90CAF9;">6608</td><td style="background-color: #90CAF9;">18585</td><td style="background-color: #90CAF9;">15010</td><td style="background-color: #90CAF9;">1695</td><td style="background-color: #90CAF9;">12640</td><td style="background-color: #90CAF9;">5402</td><td style="background-color: #90CAF9;">2742</td><td style="background-color: #90CAF9;">11</td></tr><tr><td style="background-color: #90CAF9;"><sup><xref ref-type="table-fn" rid="table2fn3">‡</xref></sup><bold>Ratio (%)</bold></td><td style="background-color: #90CAF9;">–1.36</td><td style="background-color: #90CAF9;">13.67</td><td style="background-color: #90CAF9;">18.27</td><td style="background-color: #90CAF9;">8.13</td><td style="background-color: #90CAF9;">9.87</td><td style="background-color: #90CAF9;">19.64</td><td style="background-color: #90CAF9;">19.03</td><td style="background-color: #90CAF9;">17.69</td><td style="background-color: #90CAF9;">16.03</td><td style="background-color: #90CAF9;">8.17</td><td style="background-color: #90CAF9;">12.97</td><td style="background-color: #90CAF9;">0.04</td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>2</bold></sub></italic><bold>_o</bold></td><td align="left" valign="bottom">2946</td><td align="left" valign="bottom">233</td><td align="left" valign="bottom">287</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">489</td><td align="left" valign="bottom">1662</td><td align="left" valign="bottom">1052</td><td align="left" valign="bottom">29</td><td align="left" valign="bottom">1176</td><td align="left" valign="bottom">816</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">46</td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>2</bold></sub></italic><bold>_e</bold></td><td align="left" valign="bottom">1750</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">20</td><td align="left" valign="bottom">25</td><td align="left" valign="bottom">169</td><td align="left" valign="bottom">280</td><td align="left" valign="bottom">196</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">210</td><td align="left" valign="bottom">171</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">29</td></tr><tr><td style="background-color: #90CAF9;"><bold>Excess</bold></td><td style="background-color: #90CAF9;">1195.61</td><td style="background-color: #90CAF9;">164.36</td><td style="background-color: #90CAF9;">266.72</td><td style="background-color: #90CAF9;">31.01</td><td style="background-color: #90CAF9;">320.48</td><td style="background-color: #90CAF9;">1381.54</td><td style="background-color: #90CAF9;">855.77</td><td style="background-color: #90CAF9;">26.08</td><td style="background-color: #90CAF9;">966.42</td><td style="background-color: #90CAF9;">645.41</td><td style="background-color: #90CAF9;">35.81</td><td style="background-color: #90CAF9;">16.75</td></tr><tr><td style="background-color: #90CAF9;"><bold>Ratio (%)</bold></td><td style="background-color: #90CAF9;">40.58</td><td style="background-color: #90CAF9;">70.54</td><td style="background-color: #90CAF9;">92.93</td><td style="background-color: #90CAF9;">55.37</td><td style="background-color: #90CAF9;">65.54</td><td style="background-color: #90CAF9;">83.13</td><td style="background-color: #90CAF9;">81.35</td><td style="background-color: #90CAF9;">89.93</td><td style="background-color: #90CAF9;">82.18</td><td style="background-color: #90CAF9;">79.09</td><td style="background-color: #90CAF9;">70.22</td><td style="background-color: #90CAF9;">36.42</td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>3</bold></sub></italic><bold>_o</bold></td><td align="left" valign="bottom">99</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">42</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">28</td><td align="left" valign="bottom">91</td><td align="left" valign="bottom">52</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">79</td><td align="left" valign="bottom">60</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">9</td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>3</bold></sub></italic><bold>_e</bold></td><td align="left" valign="bottom">15.43</td><td align="left" valign="bottom">0.12</td><td align="left" valign="bottom">0.02</td><td align="left" valign="bottom">0.03</td><td align="left" valign="bottom">0.47</td><td align="left" valign="bottom">1.03</td><td align="left" valign="bottom">0.60</td><td align="left" valign="bottom">0.00</td><td align="left" valign="bottom">0.66</td><td align="left" valign="bottom">0.48</td><td align="left" valign="bottom">0.01</td><td align="left" valign="bottom">0.03</td></tr><tr><td style="background-color: #90CAF9;"><bold>Excess</bold></td><td style="background-color: #90CAF9;">83.57</td><td style="background-color: #90CAF9;">17.88</td><td style="background-color: #90CAF9;">41.98</td><td style="background-color: #90CAF9;">13.97</td><td style="background-color: #90CAF9;">27.53</td><td style="background-color: #90CAF9;">89.97</td><td style="background-color: #90CAF9;">51.40</td><td style="background-color: #90CAF9;">6.00</td><td style="background-color: #90CAF9;">78.34</td><td style="background-color: #90CAF9;">59.52</td><td style="background-color: #90CAF9;">8.99</td><td style="background-color: #90CAF9;">8.97</td></tr><tr><td style="background-color: #90CAF9;"><bold>Ratio (%)</bold></td><td style="background-color: #90CAF9;">84.42</td><td style="background-color: #90CAF9;">99.32</td><td style="background-color: #90CAF9;">99.95</td><td style="background-color: #90CAF9;">99.81</td><td style="background-color: #90CAF9;">98.32</td><td style="background-color: #90CAF9;">98.86</td><td style="background-color: #90CAF9;">98.84</td><td style="background-color: #90CAF9;">99.98</td><td style="background-color: #90CAF9;">99.16</td><td style="background-color: #90CAF9;">99.20</td><td style="background-color: #90CAF9;">99.86</td><td style="background-color: #90CAF9;">99.63</td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>4</bold></sub></italic><bold>_o</bold></td><td align="left" valign="bottom">23</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">8</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">23</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">23</td><td align="left" valign="bottom">11</td><td align="left" valign="bottom">4</td><td align="left" valign="bottom">3</td></tr><tr><td align="left" valign="bottom"><italic><bold>A</bold><sub><bold>4</bold></sub></italic><bold>_e</bold></td><td align="left" valign="bottom">0.13593</td><td align="left" valign="bottom">0.00022</td><td align="left" valign="bottom">1.98E-05</td><td align="left" valign="bottom">2.81E-05</td><td align="left" valign="bottom">0.00132</td><td align="left" valign="bottom">0.00381</td><td align="left" valign="bottom">0.00185</td><td align="left" valign="bottom">4.00E-07</td><td align="left" valign="bottom">0.00210</td><td align="left" valign="bottom">0.00135</td><td align="left" valign="bottom">1.04E-05</td><td align="left" valign="bottom">3.78E-05</td></tr><tr><td style="background-color: #90CAF9;"><bold>Excess</bold></td><td style="background-color: #90CAF9;">22.8641</td><td style="background-color: #90CAF9;">9.99978</td><td style="background-color: #90CAF9;">7.99998</td><td style="background-color: #90CAF9;">1.99997</td><td style="background-color: #90CAF9;">13.9987</td><td style="background-color: #90CAF9;">22.9962</td><td style="background-color: #90CAF9;">20.9981</td><td style="background-color: #90CAF9;">3</td><td style="background-color: #90CAF9;">22.9979</td><td style="background-color: #90CAF9;">10.9987</td><td style="background-color: #90CAF9;">3.99999</td><td style="background-color: #90CAF9;">2.99999</td></tr><tr><td style="background-color: #90CAF9;"><bold>Ratio (%)</bold></td><td style="background-color: #90CAF9;">99.41</td><td style="background-color: #90CAF9;">100</td><td style="background-color: #90CAF9;">100</td><td style="background-color: #90CAF9;">100</td><td style="background-color: #90CAF9;">99.99</td><td style="background-color: #90CAF9;">99.98</td><td style="background-color: #90CAF9;">99.99</td><td style="background-color: #90CAF9;">100.00</td><td style="background-color: #90CAF9;">99.99</td><td style="background-color: #90CAF9;">99.99</td><td style="background-color: #90CAF9;">100</td><td style="background-color: #90CAF9;">100.00</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><label>*</label><p>The notation of ‘<bold>o’</bold> and ‘<bold>e’</bold> following <bold><italic>A<sub>i</sub></italic></bold>s represents the observed <bold><italic>A<sub>i</sub></italic></bold> and expected <bold><italic>A<sub>i</sub></italic></bold>.</p></fn><fn id="table2fn2"><label>†</label><p>See ‘Methods’ for the calculation of expected <bold><italic>A<sub>i</sub> ’</italic></bold>s.</p></fn><fn id="table2fn3"><label>‡</label><p>Ratio is the proportion of observed sites in excess, that is, the proportion of putative CDNs in the observation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>CDNs and the amino acids affected</title><p>We now ask whether the amino acid changes associated with CDNs bear the signatures of positive selection. Amino acids that have divergent physico-chemical properties have been shown to be under strong selection, both positive and negative (<xref ref-type="bibr" rid="bib12">Chen et al., 2019a</xref>; <xref ref-type="bibr" rid="bib13">Chen et al., 2019b</xref>; <xref ref-type="bibr" rid="bib15">Chen et al., 2022b</xref>). We note that, in almost all cases in cancer evolution, when a codon is altered, only one nucleotide of the triplet codon is changed. Among the 190 amino acid (AA, 20×19/2) pairs, only 75 of the pairs differ by 1 bp (<xref ref-type="bibr" rid="bib52">Tang et al., 2004</xref>). For example, Pro (CCN) and Ala (GCN) may differ by only 1 bp but Pro and Gly (GGN) must differ by at least 2 bp. These 75 AA changes, referred to as the elementary AA changes (<xref ref-type="bibr" rid="bib21">Grantham, 1974</xref>; <xref ref-type="bibr" rid="bib29">Li et al., 1985</xref>; <xref ref-type="bibr" rid="bib66">Yang et al., 2003</xref>; <xref ref-type="bibr" rid="bib34">Meyer et al., 2021</xref>), account for almost all AA substitutions in somatic evolution.</p><p>In a series of studies (<xref ref-type="bibr" rid="bib52">Tang et al., 2004</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2019a</xref>; <xref ref-type="bibr" rid="bib13">Chen et al., 2019b</xref>), we have defined the physico-chemical distances between AAs of the 75 elementary pairs as <inline-formula><mml:math id="inf7"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula>, where <italic>i</italic> = 1–75. <inline-formula><mml:math id="inf8"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> reflects 47 measures of AA differences including hydrophobicity, size, charge, etc., and ranges between 0 and 1. The most similar pair, Ser and Thr, has  <inline-formula><mml:math id="inf9"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> = 0, and the most dissimilar pair is Asp and Try with  <inline-formula><mml:math id="inf10"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> = 1. These studies show that <inline-formula><mml:math id="inf11"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> is a strong determinant of the evolutionary rates of DNA sequences and that large-step changes (i.e., large <inline-formula><mml:math id="inf12"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> s) are more acutely ‘recognized’ by natural selection. These large-step changes are either highly deleterious or highly advantageous. Most strikingly, advantageous mutations are enriched with AA pairs of <inline-formula><mml:math id="inf13"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> &gt; 0.8 (<xref ref-type="bibr" rid="bib12">Chen et al., 2019a</xref>).</p><p>To analyze the properties of CDNs, we choose six cancer types from <xref ref-type="table" rid="table1">Table 1</xref> that have the largest sample sizes (<bold>n</bold> &gt; 500) but leap over kidney since kidney cancers have unusually low CDN counts. In <xref ref-type="fig" rid="fig2">Figure 2</xref>, we divide the CDNs into groups according to the number of recurrences, <italic>i</italic>. CDNs of similar <italic>i</italic>s are merged into the same group in the descending order of <italic>i</italic>, until there are at least 10 CDNs in the group. The six cancer types show two clear trends: (1) the proportion of CDNs with <inline-formula><mml:math id="inf14"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> &gt; 0.8 (red color segments) increases in groups with higher recurrences; and (2) in contrast, the proportion of CDNs with <inline-formula><mml:math id="inf15"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> &lt; 0.4 (green segments) decreases as recurrences increase. These two trends would mean that highly recurrent CDNs tend to involve larger AA distances (<inline-formula><mml:math id="inf16"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> &gt; 0.8) and similar AAs tend not to manifest strong fitness increases. In general, CDNs alter amino acids in ways that expose the changes to strong selection.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><inline-formula><mml:math id="inf17"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> analysis across six cancer types.</title><p><inline-formula><mml:math id="inf18"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula>, ranging between 0 and 1 (<xref ref-type="bibr" rid="bib52">Tang et al., 2004</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2019a</xref>), is a measure of physico-chemical differences among the 20 amino acids (see the text). The most similar amino acids have <inline-formula><mml:math id="inf19"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> near 0 and the most dissimilar ones have <inline-formula><mml:math id="inf20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> near 1. Each panel corresponds to one cancer type, with horizontal bar represents <inline-formula><mml:math id="inf21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> distribution of each recurrence group. The numbers on the left of the panel are <italic>i</italic> values and on the right are the number of sites. Note that the proportion of dark red segments increases as <italic>i</italic> increases. This figure shows that mutations at high recurrence sites (larger <italic>i</italic>s) code for amino acids that are chemically very different from the wild type.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99341-fig2-v1.tif"/></fig></sec><sec id="s2-3"><title>CDNs in relation to the genes harboring them</title><p>We shall use the term ‘CDN genes’ for genes having at least one CDN site. Since CDN genes contribute to tumorigenesis when harboring a CDN mutation, they should be considered cancer drivers as well. CDN genes have two desirable qualities for recognition as driver genes. First, CDNs are straightforward and unambiguous to define (e.g., <italic>i</italic> ≥ 3 for <bold>n</bold> &lt; 1000). In the literature, there have been multiple definitions of CDGs (<xref ref-type="bibr" rid="bib43">Reimand and Bader, 2013</xref>; <xref ref-type="bibr" rid="bib42">Porta-Pardo and Godzik, 2014</xref>; <xref ref-type="bibr" rid="bib35">Mularoni et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Arnedo-Pac et al., 2019</xref>), resulting in only modest overlaps among cancer gene lists (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>). Second, the evolutionary fitness of CDN, and hence the tumorigenic potentials of CDN genes, can be computed (Appendix 2, section ‘Quantifying evolutionary fitness of CDN’).</p><p>We now present the analyses of CDN genes using the same six cancers of <xref ref-type="fig" rid="fig2">Figure 2</xref>. Two types of CDN genes are shown in <xref ref-type="table" rid="table3">Table 3</xref>. Type I genes fulfill the conventional criterion of fast evolution with the whole-gene Ka/Ks (or dN/dS) significantly larger than 1 (<xref ref-type="bibr" rid="bib32">Martincorena et al., 2017</xref>). Averaged across cancer types, type I overlaps by 95.7% with the canonical CDG list, which is the union of three popular lists (<xref ref-type="bibr" rid="bib5">Bailey et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Sondka et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Martínez-Jiménez et al., 2020</xref>). Type I genes are mostly well-known canonical CDGs (e.g., <italic>TP53</italic>, <italic>PIK3CA</italic>, and <italic>EGFR</italic>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Distribution of cancer-driving nucleotides (CDNs) among genes.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">CDN calls based on <italic>i<sup><xref ref-type="table-fn" rid="table3fn1">*</xref></sup></italic>=3</th><th align="left" valign="bottom">Lung</th><th align="left" valign="bottom">Breast</th><th align="left" valign="bottom">Central nervous system</th><th align="left" valign="bottom">Upper aerodigestive tract</th><th align="left" valign="bottom">Colon</th><th align="left" valign="bottom">Endometrium</th><th align="left" valign="bottom">Mean</th><th align="left" valign="bottom"><sup><xref ref-type="table-fn" rid="table3fn2">†</xref></sup>Total</th><th align="left" valign="bottom">Overlap with the conventional set</th><th align="left" valign="bottom">Criteria of classification</th></tr></thead><tbody><tr><td align="left" valign="bottom"># of patients<break/>(n)</td><td align="left" valign="bottom">1035</td><td align="left" valign="bottom">963</td><td align="left" valign="bottom">873</td><td align="left" valign="bottom">688</td><td align="left" valign="bottom">571</td><td align="left" valign="bottom">465</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">CDN count</td><td align="left" valign="bottom">178</td><td align="left" valign="bottom">50</td><td align="left" valign="bottom">83</td><td align="left" valign="bottom">77</td><td align="left" valign="bottom">148</td><td align="left" valign="bottom">142</td><td align="left" valign="bottom">113.3</td><td align="left" valign="bottom">495</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom" colspan="11"><bold># CDN-carrying genes (type I fulfills the convention of</bold> <sup><xref ref-type="table-fn" rid="table3fn3">‡</xref></sup><bold>Ka</bold><bold>/Ks</bold> <bold>&gt; 1**; type II does not</bold>)</td></tr><tr><td align="left" valign="bottom">Type I<break/>(Ka/Ks &gt;1<sup>**</sup>)</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">8</td><td align="left" valign="bottom">12</td><td align="left" valign="bottom">13</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">12.33</td><td align="left" valign="bottom">45</td><td align="left" valign="bottom">95.7%</td><td align="left" valign="bottom">Conventional</td></tr><tr><td align="left" valign="bottom">Type II<break/>(Ka/Ks ~1)</td><td align="left" valign="bottom">79</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">12</td><td align="left" valign="bottom">19</td><td align="left" valign="bottom">86</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">40</td><td align="left" valign="bottom">229</td><td align="left" valign="bottom">26.1%</td><td align="left" valign="bottom">This study only</td></tr><tr><td align="left" valign="bottom">All CDN genes</td><td align="left" valign="bottom">89</td><td align="left" valign="bottom">17</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">32</td><td align="left" valign="bottom">96</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">52.33</td><td align="left" valign="bottom">258</td><td align="left" valign="bottom">47%</td><td align="left" valign="bottom">Both types</td></tr><tr><td align="left" valign="bottom">Genes with 1–2 CDNs<break/>(% all CDN genes)</td><td align="left" valign="bottom">80<break/>(89.9 %)</td><td align="left" valign="bottom">14<break/>(82.4 %)</td><td align="left" valign="bottom">19<break/>(79.2 %)</td><td align="left" valign="bottom">27<break/>(84.4 %)</td><td align="left" valign="bottom">90<break/>(93.8 %)</td><td align="left" valign="bottom">45<break/>(80.4 %)</td><td align="left" valign="bottom">45.8<break/>(85 %)</td><td align="left" valign="bottom">250<break/>(96.9%)</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">A subset of both types</td></tr><tr><td align="left" valign="bottom" colspan="11"><bold>Number of driver genes in three major CDG lists</bold></td></tr><tr><td align="left" valign="bottom"><xref ref-type="table-fn" rid="table3fn1">*</xref><bold>Other criteria</bold>:</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">  </td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">–</td><td align="left" valign="bottom">Variable (see legends)</td></tr><tr><td align="left" valign="bottom">IntOGen</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">100</td><td align="char" char="." valign="bottom">100</td><td align="char" char="." valign="bottom">106</td><td align="char" char="." valign="bottom">86</td><td align="char" char="." valign="bottom">72</td><td align="char" char="." valign="bottom">97</td><td align="char" char="." valign="bottom">321</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Bailey et al.</td><td align="char" char="." valign="bottom">36</td><td align="char" char="." valign="bottom">29</td><td align="char" char="." valign="bottom">32</td><td align="char" char="." valign="bottom">38</td><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">55</td><td align="char" char="." valign="bottom">35</td><td align="char" char="." valign="bottom">134</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">CGC Tier 1</td><td align="char" char="." valign="bottom">30</td><td align="char" char="." valign="bottom">32</td><td align="char" char="." valign="bottom">32</td><td align="char" char="." valign="bottom">24</td><td align="char" char="." valign="bottom">44</td><td align="char" char="." valign="bottom">23</td><td align="char" char="." valign="bottom">30.83</td><td align="char" char="." valign="bottom">118</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table><table-wrap-foot><fn id="table3fn1"><label>*</label><p>intOGen, Bailey et al., and CGC Tier 1 are the three major CDG lists adopted here for comparison (<xref ref-type="bibr" rid="bib5">Bailey et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Sondka et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Martínez-Jiménez et al., 2020</xref>).</p></fn><fn id="table3fn2"><label>†</label><p>”Total” refers to the cumulative number of unique genes identified across all six cancer types.</p></fn><fn id="table3fn3"><label>‡</label><p>Here, ** denotes significant Ka/Ks results with a corrected q-value &lt; 0.1 based on dndscv analysis.</p></fn></table-wrap-foot></table-wrap><p>Type II (CDN genes) is the new class of CDGs. These genes have CDNs but do not meet the conventional criteria of whole-gene analysis. Obviously, if a gene has only one or two CDNs plus some sporadic hits, the whole-gene Ka/Ks would not be significantly greater than 1. As shown in <xref ref-type="table" rid="table3">Table 3</xref>, over 80% of CDN genes have only 1–2 CDN sites. The salient result is that type II genes outnumber type I genes by a ratio of 5:1 (229:45, column 8, <xref ref-type="table" rid="table3">Table 3</xref>). Furthermore, type II genes overlap with the canonical CDG list by only 23%.</p><p>Type II genes represent a new class of cancer drivers that concentrate their tumorigenic strength on a small number CDN sites. They have been missed by the conventional whole-gene definition of cancer drivers. One such example is the <italic>FGFR3</italic> gene in lung cancer. This gene of 809 codons has only eight hits, among which one is a CDN (<italic>i</italic> = 3) in lung cancer. It is noticed solely for this CDN. In Appendix 2, section ‘Functional annotation of new cancer drivers’, we briefly annotate these new CDGs for comparisons with the canonical driver genes. Possible functional tests in the future can be found in ‘Discussion’.</p><p>We now briefly discuss the driver genes listed in previous studies as shown at the lower part of <xref ref-type="table" rid="table3">Table 3</xref> (<xref ref-type="bibr" rid="bib5">Bailey et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Sondka et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Martínez-Jiménez et al., 2020</xref>). From the total number of CDGs listed, it is clear that the overlaps are limited. As analyzed before (<xref ref-type="bibr" rid="bib61">Wu et al., 2016</xref>), conventional gene lists overlap mainly by a core set of high Ka/Ks genes. This core set has not changed much as various criteria such as the replication timing, expression profiles, and epigenetic features are introduced. These criteria are the reasons for the many CDGs recognized by only a small subset of CDG lists. CDN genes, in contrast, can be objectively defined as CDN mutations (<italic>i</italic> recurrences in <bold>n</bold> samples) themselves are unambiguous.</p><sec id="s2-3-1"><title>Variation in CDN number and tumorigenic contribution among genes</title><p>By and large, the distribution of CDNs among genes is very uneven. <xref ref-type="fig" rid="fig3">Figure 3A</xref> shows 10 genes with at least six CDNs, whereas 87 genes have only one CDN. Two genes stand out for the number of CDNs they harbor, <italic>TP53</italic> and <italic>PIK3CA</italic>, which also happen to be the only genes mutated in &gt;15% of all cancer patients surveyed (<xref ref-type="bibr" rid="bib26">Kandoth et al., 2013</xref>). Clearly, the prevalence of mutations in a gene is a function of the number of strong CDNs it harbors.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Distribution of cancer-driving nucleotides (CDNs) among genes.</title><p>(<bold>A</bold>) Out of 119 CDN-carrying genes (red bars), 87 have only one CDN. For the rest, <italic>TP53</italic> possesses the most CDNs with three others having more than 10 CDNs. (<bold>B</bold>) CDN number in <italic>TP53</italic> among patients. The dark bar represents the observed patient number with corresponding CDNs of the X-axis. The gray bar shows the expected patient distribution. Clearly, <italic>TP53</italic> only needs to contribute one CDN to drive tumorigenesis. Hence, <italic>TP53</italic> (and other canonical driver genes; see text), while prevalent, does not contribute disproportionately to the tumorigenesis of each patient.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99341-fig3-v1.tif"/></fig><p>Although a small number of genes have unusually high number of CDNs, these genes may not drive the tumorigenesis in proportion to their CDN numbers in individual patients. <xref ref-type="fig" rid="fig3">Figure 3B</xref> shows the number of CDN mutations on <italic>TP53</italic> that occur in any single patient. Usually, only one CDN change is observed in a patient, whereas two or three CDN mutations are expected. It thus appears that CDNs on the same genes are redundant in their tumorigenic effects such that the second hit may not yield additional advantages. This pattern of disproportionally lower contribution by CDN-rich genes is true in other genes such as <italic>EGFR</italic> and <italic>KRAS</italic>. Consequently, the large number of genes with only one or two CDN sites are disproportionately important in driving the tumorigenesis of individual patients.</p></sec></sec><sec id="s2-4"><title>CDNs in relation to the cancer types: The pan-cancer properties</title><p>In the current literature, CDGs (however they are defined) generally meet the statistical criteria for driver genes in only one or a few cancer types. However, genes may in fact contribute to tumorigenesis but are insufficiently prevalent to meet the statistical requirements for CDGs. Many genes are indeed marginally qualified as drivers in some tissues and barely miss the statistical cutoff in others. To see if genes that drive tumorigenesis in multiple tissues are more common than currently understood, we need to raise the sensitivity of cancer driver detection. Thus, CDNs may provide the resolution.</p><p>To test the pan-cancer-driving capacity of CDNs, we define <italic>i<sub>max</sub></italic> as the largest <italic>i</italic> values among the 12 cancer types for each CDN. The number of cancer types where the said mutation can be detected (i.e., <italic>i</italic> &gt; 0) is designated NC12. <xref ref-type="fig" rid="fig4">Figure 4</xref> presents the relationship between the observed NC12 of each CDN against <italic>i<sub>max</sub></italic> of that CDN. Clearly, many CDNs are observed in multiple cancer types (NC12 &gt; 3), even though they do not qualify as a driver gene in all but a single cancer type. It happens frequently when a mutation has <italic>i</italic> &gt; 3 in one cancer type but has <italic>i</italic> &lt; 3 in others. One extreme example is C394 and G395 in <italic>IDH1</italic>. In central nervous system (CNS), both sites show <italic>i</italic> ≫ 3, while in six other cancer types (lung, breast, large intestine, prostate, urinary tract, liver), their hits are <italic>i</italic> &lt; 3 but &gt; 0. Conditional on a specific site informed by a cancer type, a mutation in another cancer type should be very unlikely if the mutation is not tumorigenic in multiple tissues. Hence, the pattern in <xref ref-type="fig" rid="fig4">Figure 4</xref> is interpreted to be drivers in multiple cancer types, but with varying statistical strength.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Sharing of cancer-driving nucleotides (CDNs) across cancer types.</title><p>The X-axis shows <italic>i<sub>max</sub></italic>, which is the largest <italic>i</italic> a CDN reaches among the 12 cancer types. The Y-axis shows the number of cancer types where the mutation also occurs. Each dot is a CDN, and the number of dots in the cloud is given. The blue and red dots denote, respectively, mutations classified as a CDN in one or multiple cancer types. Gray dots are non-CDNs. The table in the lower panel summarizes the number of sites and the number of genes harboring these sites.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99341-fig4-v1.tif"/></fig><p>Examining <xref ref-type="fig" rid="fig4">Figure 4</xref> more carefully, we could see that CDNs with a larger <italic>i<sub>max</sub></italic> in one cancer type are more likely to be identified as CDNs in multiple cancer types (red dots, <italic>r</italic> = 0.97, p=9.23 × 10<sup>–5</sup>, Pearson’s correlation test). Of 22 sites with <italic>i<sub>max</sub></italic> &gt; 20, 15 are identified as CDNs (<italic>i</italic> ≥ 3) in multiple cancer types, with a median NC12 of 9. On the opposite end, two CDNs with <italic>i<sub>max</sub></italic> &gt; 20 are observed in only one cancer type (<italic>EGFR</italic>: T2573 in lung and <italic>FGFR2</italic>: C755 in endometrium cancer). The bimodal pattern suggests that a few cancer driver mutations are tissue specific, whereas most others appear to have pan-cancer-driving potentials.</p><p>To conclude, when a driver is observed in more than one cancer type, it is often a cancer driver in many others, but insufficiently powerful to meet the statistical criteria for driver mutations. This pan-cancer property can be seen at the higher resolution of CDN, but is often missed at the whole-gene level. Cancers of the same tissue in different patients, often reported to have divergent mutation profiles (<xref ref-type="bibr" rid="bib38">Nik-Zainal et al., 2012</xref>; <xref ref-type="bibr" rid="bib44">Roberts and Gordenin, 2014</xref>), should be a good test of this hypothesis.</p></sec><sec id="s2-5"><title>CDNs in relation to individual patients and therapeutic strategies</title><p>In previous sections, the focus is on the population of cancer patients; for example, how many in the patient population have certain mutations. We now direct the attention to individual patients. It would be necessary to pinpoint the CDN mutations in each patient in order to delineate the specific evolutionary path and to devise the treatment strategy. We shall first address the cancer-driving power of CDN vs. non-CDN mutations in the same gene.</p><sec id="s2-5-1"><title>Efficacy of targeted therapy against CDNs vs. non-CDNs</title><p>In general, a patient would have many point mutations, only a few of which are strong CDNs. We may ask whether most mutations on the canonical genes, such as <italic>EGFR</italic>, are CDNs. Presumably, synonymous, and likely many nonsynonymous, mutations on canonical genes may not be CDNs. It would be logical to hypothesize that patients whose <italic>EGFR</italic> has a CDN mutation (group 1 patients) should benefit from the gene-targeted therapy more than patients with a non-CDN mutation on the same gene (group 2 patients). In the second group, <italic>EFGR</italic> may be a nondriver of tumorigenesis.</p><p>Published data (<xref ref-type="bibr" rid="bib2">André et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Choudhury et al., 2023</xref>) are re-analyzed as shown in <xref ref-type="fig" rid="fig5">Figure 5</xref>. The hypothesis that patients of group 2 would not benefit as much as those of group 1 is supported by the analysis. This pattern further strengthens the underlying assumption that non-CDN mutations, even on canonical genes, are not cancer drivers.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Survival analysis of non-small cell lung cancer (NSCLC) patients based on EGFR mutation status.</title><p>Patient data were retrieved from the GENIE database (<ext-link ext-link-type="uri" xlink:href="https://genie-public-beta.cbioportal.org/">https://genie-public-beta.cbioportal.org/</ext-link>) and stratified into three groups based on <italic>EGFR</italic> mutation profiles: Group 1 comprises patients with <italic>EGFR</italic> CDN mutations; group 2 includes patients with nonsynonymous mutations in <italic>EGFR</italic> that are not cancer-driving nucleotides (CDNs); the <italic>EGFR<sup>WT</sup></italic> group consists of patients with no <italic>EGFR</italic> mutations (see ‘Methods’). Patients of groups 1 and 2 received <italic>EGFR</italic>-targeted therapies in accordance with the guidelines for managing <italic>EGFR</italic> mutant NSCLC (<xref ref-type="bibr" rid="bib41">Passaro et al., 2022</xref>; <xref ref-type="bibr" rid="bib16">Choudhury et al., 2023</xref>). Survival analysis using the Kaplan–Meier method revealed a significantly higher survival rate for group 1 patients compared to group 2 and the <italic>EGFR<sup>WT</sup></italic> group (p&lt;0.001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99341-fig5-v1.tif"/></fig></sec><sec id="s2-5-2"><title>Number of CDNs in each patient</title><p>We postulate that a full set of CDNs should be able to inform about the cause of each cancer as well as the design of gene-targeted therapy. In <xref ref-type="table" rid="table4">Table 4</xref>, the known CDNs based on TCGA are tallied. Note that only a few CDNs fall on the canonical driver genes, whereas most CDNs fall on the nonconventional ones.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Numbers of patients with cancer-driving nucleotides (CDNs) vs. number of patients with any non-synonymous mutations in the same genes.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="2">Lung</th><th align="left" valign="bottom" colspan="2">Breast</th><th align="left" valign="bottom" colspan="2">Central nervous system</th><th align="left" valign="bottom" colspan="2">Upper aerodigestive tract</th><th align="left" valign="bottom" colspan="2">Colon</th><th align="left" valign="bottom" colspan="2">Endometrium</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>CDN</bold><xref ref-type="table-fn" rid="table4fn1">*</xref><sup><xref ref-type="table-fn" rid="table4fn2">†</xref></sup><break/>(178)</td><td align="left" valign="bottom"><bold>Gene</bold><xref ref-type="table-fn" rid="table4fn2"><sup>†</sup></xref> <xref ref-type="table-fn" rid="table4fn3"><sup><bold>‡</bold></sup></xref><break/><bold>(89)</bold></td><td align="left" valign="bottom"><bold>CDN</bold><break/>(50)</td><td align="left" valign="bottom"><bold>Gene</bold><break/>(17)</td><td align="left" valign="bottom"><bold>CDN</bold><break/>(83)</td><td align="left" valign="bottom"><bold>Gene</bold><break/>(24)</td><td align="left" valign="bottom"><bold>CDN</bold><break/>(77)</td><td align="left" valign="bottom"><bold>Gene</bold><break/>(32)</td><td align="left" valign="bottom"><bold>CDN</bold><break/>(148)</td><td align="left" valign="bottom"><bold>Gene</bold><break/>(96)</td><td align="left" valign="bottom"><bold>CDN</bold><break/>(142)</td><td align="left" valign="bottom"><bold>Gene</bold><break/>(56)</td></tr><tr><td align="left" valign="bottom"><bold>n<sub>0</sub></bold></td><td align="left" valign="bottom">342<break/>(33%) <xref ref-type="table-fn" rid="table4fn4"><sup>§</sup></xref></td><td align="left" valign="bottom">53<break/>(5.3%)</td><td align="left" valign="bottom">492<break/>(51.1%)</td><td align="left" valign="bottom">415<break/>(43.1%)</td><td align="left" valign="bottom">235<break/>(26.9%)</td><td align="left" valign="bottom">163<break/>(18.7%)</td><td align="left" valign="bottom">268<break/>(39%)</td><td align="left" valign="bottom">140<break/>(20.3%)</td><td align="left" valign="bottom">102<break/>(17.9%)</td><td align="left" valign="bottom">42<break/>(7.4%)</td><td align="left" valign="bottom">42<break/>(9%)</td><td align="left" valign="bottom">14<break/>(3%)</td></tr><tr><td align="left" valign="bottom"><bold>n<sub>1</sub></bold></td><td align="left" valign="bottom">411<break/>(39.7%)</td><td align="left" valign="bottom">70<break/>(6.8%)</td><td align="left" valign="bottom">379<break/>(39.4%)</td><td align="left" valign="bottom">395<break/>(41%)</td><td align="left" valign="bottom">359<break/>(41.1%)</td><td align="left" valign="bottom">306<break/>(35.1%)</td><td align="left" valign="bottom">268<break/>(39%)</td><td align="left" valign="bottom">229<break/>(33.3%)</td><td align="left" valign="bottom">159<break/>(27.8%)</td><td align="left" valign="bottom">79<break/>(13.8%)</td><td align="left" valign="bottom">108<break/>(23.2%)</td><td align="left" valign="bottom">59<break/>(12.7%)</td></tr><tr><td align="left" valign="bottom"><bold>n<sub>2</sub></bold></td><td align="left" valign="bottom">192<break/>(18.6%)</td><td align="left" valign="bottom">84<break/>(8.1%)</td><td align="left" valign="bottom">73<break/>(7.6%)</td><td align="left" valign="bottom">114<break/>(11.8%)</td><td align="left" valign="bottom">225<break/>(25.8%)</td><td align="left" valign="bottom">293<break/>(33.6%)</td><td align="left" valign="bottom">101<break/>(14.7%)</td><td align="left" valign="bottom">171<break/>(24.9%)</td><td align="left" valign="bottom">140<break/>(24.5%)</td><td align="left" valign="bottom">93<break/>(16.3%)</td><td align="left" valign="bottom">169<break/>(36.3%)</td><td align="left" valign="bottom">101<break/>(21.7%)</td></tr><tr><td align="left" valign="bottom"><bold>n<sub>&gt;2</sub></bold></td><td align="left" valign="bottom">90<break/>(8.7%)</td><td align="left" valign="bottom">826<break/>(79.8%)</td><td align="left" valign="bottom">18<break/>(1.9%)</td><td align="left" valign="bottom">38<break/>(3.9%)</td><td align="left" valign="bottom">53<break/>(6.1%)</td><td align="left" valign="bottom">110<break/>(12.6%)</td><td align="left" valign="bottom">50<break/>(7.3%)</td><td align="left" valign="bottom">147<break/>(21.4%)</td><td align="left" valign="bottom">170<break/>(29.8%)</td><td align="left" valign="bottom">357<break/>(62.5%)</td><td align="left" valign="bottom">146<break/>(31.4%)</td><td align="left" valign="bottom">291<break/>(62.6%)</td></tr><tr><td align="left" valign="bottom">Total <bold>n</bold></td><td align="left" valign="bottom">1035</td><td align="left" valign="bottom">1035</td><td align="left" valign="bottom">963</td><td align="left" valign="bottom">963</td><td align="left" valign="bottom">873</td><td align="left" valign="bottom">873</td><td align="left" valign="bottom">688</td><td align="left" valign="bottom">688</td><td align="left" valign="bottom">571</td><td align="left" valign="bottom">571</td><td align="left" valign="bottom">465</td><td align="left" valign="bottom">465</td></tr><tr><td align="left" valign="bottom">Mean #</td><td align="left" valign="bottom">1.06</td><td align="left" valign="bottom">7.19</td><td align="left" valign="bottom">0.61</td><td align="left" valign="bottom">0.78</td><td align="left" valign="bottom">1.12</td><td align="left" valign="bottom">1.44</td><td align="left" valign="bottom">0.93</td><td align="left" valign="bottom">1.63</td><td align="left" valign="bottom">1.96</td><td align="left" valign="bottom">4.6</td><td align="left" valign="bottom">2.17</td><td align="left" valign="bottom">3.7</td></tr></tbody></table><table-wrap-foot><fn id="table4fn1"><label>*</label><p>n<sub>i</sub> designates the number of patients with <italic>i</italic> CDN mutations.</p></fn><fn id="table4fn2"><label>†</label><p>The number in the parentheses is the total number of CDNs or genes.</p></fn><fn id="table4fn3"><label>‡</label><p>In this column, <bold>n<sub>i</sub></bold> designates the number of patients with any nonsynonymous mutation in the same gene as the CDN column.</p></fn><fn id="table4fn4"><label>§</label><p>There are 684 CDNs summed over all cancer types. The percentage is <bold>n<sub>i</sub></bold>/Total <bold>n.</bold></p></fn></table-wrap-foot></table-wrap><p>In most cancer types, 10–30% of patients, shown in the <bold>n<sub>0</sub></bold> row of <xref ref-type="table" rid="table4">Table 4</xref>, have no known CDNs (and &gt;50% among breast cancer patients). Hence, the current practice is to rely on missense mutations, regardless of CDNs or non-CDNs, on the canonical genes. The CDN column vs. the gene column in <xref ref-type="table" rid="table4">Table 4</xref> addresses this issue. For example, the CDN column suggests that 33% of lung cancer patients (the <bold>n<sub>0</sub></bold> row) would not respond well to gene-targeted therapy, whereas the gene column shows only 5.3%. The difference is due to a higher, and likely inflated, detection rate of candidate drivers in the gene column. We suggest that patients who have a non-CDN mutation on a driver gene would not respond to the targeted therapy against that gene, as demonstrated in <xref ref-type="fig" rid="fig5">Figure 5</xref>. In the above example, 27.7% (33–5.3%) of patients may be subjected to the targeted treatment but may not respond well.</p></sec><sec id="s2-5-3"><title>Prevalence vs. potency of CDN-bearing genes in driving tumorigenesis</title><p>The last question is the relationship between mutation prevalence and tumorigenic strength (or potency) among CDN-bearing genes. For example, when a patient is diagnosed to have five CDNs in five genes, what may be their relative contributions to the tumorigenesis? Are they equally valid candidates for targeted therapy? It would seem logical that canonical CDGs with many CDNs should be the targets. However, because these genes would contribute at most one CDN to the tumorigenesis (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), targeting a high-prevalence gene may not yield more benefits to the patients than targeting a low-prevalence gene that has a CDN.</p><p>The implication is that prevalence and potency of CDNs may not be strongly correlated. Some genes may be prevalently mutated in the patient population but, in each affected patient, these genes may not be more potent than the less prevalent genes with a CDN mutation. Potency can be tested in vitro by gene editing or in vivo by targeting treatment. In this interpretation, targeting a CDN of low prevalence (say, <italic>i</italic> = 3) may be as effective in treatment as targeting a high-prevalence CDN with <italic>i</italic> = 20. The model and <xref ref-type="table" rid="table5">Table 5</xref> present this hypothesis based on cancer hallmarks.</p><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Gene numbers for different cancer hallmarks.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="3">Gene number</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Hallmark</bold></td><td align="left" valign="bottom"><bold>All records</bold></td><td align="left" valign="bottom"><bold>Breast</bold></td><td align="left" valign="bottom"><bold>Colon</bold></td></tr><tr><td align="left" valign="bottom">Angiogenesis</td><td align="char" char="." valign="bottom">78</td><td align="char" char="." valign="bottom">8</td><td align="char" char="." valign="bottom">6</td></tr><tr><td align="left" valign="bottom">Cell division control</td><td align="char" char="." valign="bottom">107</td><td align="char" char="." valign="bottom">12</td><td align="char" char="." valign="bottom">10</td></tr><tr><td align="left" valign="bottom">Cell replicative immortality</td><td align="char" char="." valign="bottom">44</td><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom">Change of cellular energetics</td><td align="char" char="." valign="bottom">70</td><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">4</td></tr><tr><td align="left" valign="bottom">Escaping immune response to cancer</td><td align="char" char="." valign="bottom">51</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Escaping programmed cell death</td><td align="char" char="." valign="bottom">202</td><td align="char" char="." valign="bottom">32</td><td align="char" char="." valign="bottom">20</td></tr><tr><td align="left" valign="bottom">Genome instability and mutations</td><td align="char" char="." valign="bottom">106</td><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">7</td></tr><tr><td align="left" valign="bottom">Invasion and metastasis</td><td align="char" char="." valign="bottom">206</td><td align="char" char="." valign="bottom">52</td><td align="char" char="." valign="bottom">27</td></tr><tr><td align="left" valign="bottom">Proliferative signaling</td><td align="char" char="." valign="bottom">176</td><td align="char" char="." valign="bottom">40</td><td align="char" char="." valign="bottom">20</td></tr><tr><td align="left" valign="bottom">Senescence</td><td align="char" char="." valign="bottom">48</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">5</td></tr><tr><td align="left" valign="bottom">Suppression of growth</td><td align="char" char="." valign="bottom">130</td><td align="char" char="." valign="bottom">11</td><td align="char" char="." valign="bottom">12</td></tr><tr><td align="left" valign="bottom">Tumor-promoting inflammation</td><td align="char" char="." valign="bottom">54</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">3</td></tr></tbody></table><table-wrap-foot><fn><p>Data downloaded from COSMIC (<ext-link ext-link-type="uri" xlink:href="https://cancer.sanger.ac.uk/cosmic/download">https://cancer.sanger.ac.uk/cosmic/download</ext-link>), see ‘Methods’.</p></fn></table-wrap-foot></table-wrap><p>The hallmarks of cancer were first proposed by <xref ref-type="bibr" rid="bib22">Hanahan and Weinberg, 2000</xref> with several updates (<xref ref-type="bibr" rid="bib23">Hanahan and Weinberg, 2011</xref>; <xref ref-type="bibr" rid="bib24">Hanahan, 2022</xref>). Each hallmark is a cancer phenotype shown in <xref ref-type="table" rid="table5">Table 5</xref> that lists the number of genes involved in each particular hallmark (see ‘Methods’). While each hallmark may be associated with a number of genes, many genes are also involved in multiple hallmarks. As even the highly prevalent genes would usually have at most one mutation in each patient, we assume that each gene is associated with one hallmark in each patient.</p><p>Suppose that tumorigenesis requires a mutation in most (but perhaps not all) of the hallmarks, then the number of mutation combinations would be the product of all numbers in the corresponding column. For breast cancer, it would be 8 × 12 × 4.... × 11 × 2–1.7 × 10<sup>11</sup>. In other words, the possible mutation combinations that can drive breast cancer is over a billion. Hence, two breast cancers are unlikely to have the same set of CDGs or CDNs. In this view, the prevalence of a gene would be inversely proportional to the hallmark gene number. For example, genes of ‘<italic>invasion and metastasis’</italic> in breast cancer would have a prevalence of &lt;1/52. In contrast, the potency in tumorigenesis should depend on the hallmark phenotype itself and independent of gene number for that hallmark. In this example, each gene of ‘<italic>invasion and metastasis’</italic> may be lowly prevalent, but could also be highly potent in each patient.</p><p>In short, the prevalence and potency of CDNs may be poorly correlated. The hypothesis can be functionally tested (by gene editing in vitro or targeting treatment in vivo) in conjunction with the data on the attraction (i.e., co-occurrences) vs. repulsion (lack of co-occurrences) of CDNs.</p></sec></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The companion study presents the theory that computes the limit of recurrences (<italic>i</italic>/<bold>n</bold>, <italic>i</italic> times in <bold>n</bold> patients) of reachable by neutral mutations. Above the cutoff (e.g., 3/1000), a recurrent mutation is deemed an advantageous CDN (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>). At present, the power of CDN analysis is hampered by the still small sample sizes, generally between 300 and 3000. We show that, when <bold>n</bold> reaches 10<sup>5</sup>, a mutation only has to recur 12 times to be shown as a CDN, that is, 25 times more sensitive than 3/1000. In short, nearly all CDNs should be discovered with <bold>n</bold> ≥ 10<sup>5</sup>.</p><p>In this study, we apply the theory on existing data to characterize the discovered CDNs. Based on TCGA data, this study concludes that each cancer patient carries only 1–2 CDNs, whereas 6–10 drivers are usually hypothesized to be present in each cancer genome (<xref ref-type="bibr" rid="bib23">Hanahan and Weinberg, 2011</xref>; <xref ref-type="bibr" rid="bib55">Vogelstein et al., 2013</xref>; <xref ref-type="bibr" rid="bib9">Campbell et al., 2020</xref>). This deficit signifies the current incomplete understanding of cancer-driving potentials. Across patients of the same cancer type, about 50–150 CDNs have been discovered for each cancer type, representing perhaps only 10% of all possible CDNs. Given a complete set of CDNs, it should be possible to delineate the path of tumor evolution for each individual patient.</p><p>Direct functional test of CDNs would be to introduce putative cancer-driving mutations and observe the evolution of tumors. Such a task of introducing multiple mutations that are collectively needed to drive tumorigenesis has been done only recently and only for the best-known cancer-driving mutations (<xref ref-type="bibr" rid="bib39">Ortmann et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Takeda et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Hodis et al., 2022</xref>). In most tumors, the correct combination of mutations needed is not known. Clearly, CDNs, with their strong tumorigenic strength, are suitable candidates.</p><p>Many CDNs in a patient may not fall on conventional CDGs, whereas these conventional CDGs may have passenger or weak mutations. Therefore, the efforts in gene-targeting therapy may well be shifted to the CDN-harboring genes. Given a complete set of CDNs, many more driver genes can be identified. Since many driver genes cannot be targeted for biological or technical reasons (<xref ref-type="bibr" rid="bib18">Dang et al., 2017</xref>; <xref ref-type="bibr" rid="bib17">Danesi et al., 2021</xref>; <xref ref-type="bibr" rid="bib57">Waarts et al., 2022</xref>), a large set of CDGs will be desirable. The goal is that each cancer patient would have multiple targetable CDGs, all driven by CDNs they carry. In that case, the probability that resistance mutations eluding multiple targeting drugs should be diminished (<xref ref-type="bibr" rid="bib14">Chen et al., 2022a</xref>; <xref ref-type="bibr" rid="bib67">Zhai et al., 2022</xref>; <xref ref-type="bibr" rid="bib7">Bian et al., 2023</xref>; <xref ref-type="bibr" rid="bib30">Lin et al., 2023</xref>; <xref ref-type="bibr" rid="bib70">Zhu et al., 2023</xref>).</p><p>In this context, we should comment on the feasibility of targeting CDNs that may occur in either oncogenes (ONCs) or tumor suppressor genes (TSGs). It is generally accepted that ONCs drive tumorigenesis thanks to the gain-of-function (GOF) mutations, whereas TSGs derive their tumorigenic powers by loss-of-function (LOF) mutations. Nevertheless, since LOF mutations are likely to be widespread on TSGs, they are less likely to recur as CDNs. The even distributions of nonsense mutations along the length of many TSGs provide such evidence. Importantly, as gene targeting aims to diminish gene functions, GOF mutations are perceived to be targetable, whereas LOF mutations are not. By extension, ONCs should be targetable but TSGs are not, an assertion we address below.</p><p>The data suggest that missense mutations on TSGs may often be of the GOF kind. If missense mutations are far more prevalent than nonsense mutations in tumors, the missense mutations cannot possibly be LOF mutations. (After all, it is not possible to lose <italic>more</italic> functions than nonsense mutations.) In a separate study (<xref ref-type="bibr" rid="bib20">Deng et al., 2022</xref>), we compare missense and nonsense mutations (referred to as the escape-route analysis). For example, AAA to AAC (K to Q) is a missense mutation while the same AAA codon to AAT (K to stop) is a nonsense mutation. We found many cases where the missense mutations on TSGs are more prevalent (&gt;10×) than nonsense mutations. We interpret these missense mutations to be of the GOF kind because they could not possibly ‘lose’ more functions than the nonsense mutations.</p><p>Another interesting pattern may be the distributions of CDNs across different cancer types. Cancer evolution in different tissues represents parallel evolution driven by similar selection for cell proliferation but under different ecological conditions. <xref ref-type="fig" rid="fig4">Figure 4</xref> suggests that CDNs previously identified to be cancer-specific may have pan-cancer effects. In different cancer types, the same CDNs may drive tumorigenesis but the strength may not be sufficient to raise the data above the statistical threshold.</p><p>The CDN approach has two additional applications. First, it can be used to find CDNs in non-coding regions. Although the number of whole-genome sequences at present is still insufficient for systematic CDN detection, the preliminary analysis suggests that the density of CDNs in noncoding regions is orders of magnitude lower than in coding regions. Second, CDNs can also be used in cancer screening with the advantage of efficiency as the targeted mutations are fewer. For the same reason, the false-negative rate should be much lower too. Indeed, the false-positive rate should be far lower than the gene-based screen which often shows a false-positive rate of &gt;50% (Appendix 2, ‘The specificity of CDNs in cancer detection’).</p><p>Cancer evolution falls within the realm of ultra-microevolution (<xref ref-type="bibr" rid="bib61">Wu et al., 2016</xref>). The repeated evolution addresses the single most severe criticism of evolutionary studies, namely all evolutionary events have a sample size of one. Such repeated evolution offers the opportunity to uncover the full list of mutations underlying complex traits that is at the heart of molecular evolution. The genetics of speciation (<xref ref-type="bibr" rid="bib60">Wu and Ting, 2004</xref>; <xref ref-type="bibr" rid="bib40">Pan et al., 2022</xref>; <xref ref-type="bibr" rid="bib58">Wang et al., 2022</xref>; <xref ref-type="bibr" rid="bib63">Wu, 2023</xref>) and the emergence of major viral strains (such as COVID-19) (<xref ref-type="bibr" rid="bib20">Deng et al., 2022</xref>; <xref ref-type="bibr" rid="bib45">Ruan et al., 2022</xref>; <xref ref-type="bibr" rid="bib10">Cao et al., 2023</xref>; <xref ref-type="bibr" rid="bib46">Ruan et al., 2023</xref>) are both phenomena of complex gene interactions. The two companion studies may thus unite evolutionary biology and cancer medicine.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Data preparation</title><p>Single-nucleotide variant (SNV) data for TCGA patients were downloaded from the GDC Data Portal (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>, data version 28 February 2022), with mutations identified by at least two pipelines were included in this study. Mutations exceeding a 1‰ frequency in the Genome Aggregation Database (<italic>gnomAD</italic>, version v2.1.1) were excluded to minimize potential false positives arising from germline variants. Patients with more than 3000 coding region point mutations were filtered out as potential hypermutator phenotypes. This filtering process yielded a final analysis set encompassing 7369 patients across 12 diverse cancer types for subsequent analysis. The calculation of <bold><italic>A<sub>i</sub></italic></bold> and <bold><italic>S<sub>i</sub></italic></bold> follows the same method as described in the companion paper (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>).</p><p>For CDN analysis in noncancerous tissues, mutation profiles for normal tissues were retrieved from <italic>SomaMutDB</italic> (<xref ref-type="bibr" rid="bib49">Sun et al., 2022</xref>). Mutations from different samples originating from the same individual were consolidated. Donners above the age of 80 were excluded from our dataset. The mutation processing followed the same pipeline as previously described. In total, we have mutation profiles from 487 donners serving as a negative control.</p><p>The canonical lists of CDGs were obtained from three distinct data sources. The CGC Tier 1 genes, encompassing genes with the highest confidence of driver status, were retrieved from the COSMIC Cancer Gene Census (<ext-link ext-link-type="uri" xlink:href="https://cancer.sanger.ac.uk/census">https://cancer.sanger.ac.uk/census</ext-link>; <xref ref-type="bibr" rid="bib48">Sondka et al., 2018</xref>). The IntOGen driver gene list, which employs an integrated pipeline for gene discovery, was downloaded from <ext-link ext-link-type="uri" xlink:href="https://www.intogen.org/download">https://www.intogen.org/download</ext-link> (<xref ref-type="bibr" rid="bib33">Martínez-Jiménez et al., 2020</xref>). Bailey’s driver gene list comprises 299 CDGs identified through a <italic>PanSoftware</italic> strategy, with further experimental validation confirming their role in driving cell lines (<xref ref-type="bibr" rid="bib5">Bailey et al., 2018</xref>). The consistency of cancer types across all studies was manually verified using <italic>oncotree</italic> (#/home). For the analysis of driver gene overlap, only drivers from the same cancer type were compared.</p><p>The hallmark annotation of genes was downloaded from COSMIC (<ext-link ext-link-type="uri" xlink:href="https://cancer.sanger.ac.uk/cosmic/download">https://cancer.sanger.ac.uk/cosmic/download</ext-link>), encompassing 331 genes with annotated dysregulated biological processes. It is important to note that these hallmarks are manually annotated as part of an ongoing effort to characterize the role of genes in cancer based on literature evidence. The actual scale of hallmark genes may be substantially larger than the current version.</p><p>For gene-level selection analysis, we utilized the R package '<italic>dndscv</italic>' to quantify selection signals for missense and nonsense mutations in a given gene (<xref ref-type="bibr" rid="bib32">Martincorena et al., 2017</xref>). Specifically, the package calculates the Ka/Ks ratio, denoted as '<bold><italic>w</italic></bold>' in the final results, for a given mutation impact (missense or nonsense). The significance of selection is presented as <italic>q</italic> values after Benjamini–Hochberg (BH) adjustment. Genes with <bold><italic>w</italic></bold> &gt; 1 and <italic>q</italic> &lt; 0.1 were identified as being significantly under positive selection.</p><p>We employ <italic>i<sup>*</sup></italic> = 3 as a cutoff for identifying CDNs across various cancer types. The specific value of <italic>i<sup>*</sup></italic> is detailed in Eq. 10 of the companion paper (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>). Here, <italic>i<sup>*</sup></italic> = 3 is chosen consistently across all cancer types, taking into account the abundance of sites under positive selection given <italic>i</italic> = 3 in <xref ref-type="table" rid="table2">Table 2</xref>. Throughout our analysis, emphasis is placed on CDNs of the missense category, where missense mutations with a recurrence ≥3 are identified as CDNs. For <inline-formula><mml:math id="inf22"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> analysis, the reference table for 75 single-step amino acid changes was obtained from <xref ref-type="bibr" rid="bib12">Chen et al., 2019a</xref>, and the <inline-formula><mml:math id="inf23"><mml:mi>Δ</mml:mi><mml:mi>U</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> for each CDN is derived by mapping the amino acid change to the reference table.</p></sec><sec id="s4-2"><title>Calculation of <italic>A<sub>i</sub></italic>_e</title><p>We employ Eq. 9 from the companion paper to calculate the expected value for <bold><italic>A<sub>i</sub></italic></bold> under neutrality. For a given site, the cumulative probability for recurrence <inline-formula><mml:math id="inf24"><mml:mi>x</mml:mi><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula> could be expressed as<disp-formula id="equ1"><label>(S1)</label><mml:math id="m1"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>n</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>u</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <bold>n</bold> is the population size of a given cancer type, and <bold>E(u)</bold> is the mutation rate per site per patient derived from singleton synonymous mutations:<disp-formula id="equ2"><label>(S2)</label><mml:math id="m2"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>n</mml:mi><mml:mi>E</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:mfenced><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mi>n</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mi>E</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msup></mml:math></disp-formula></p><p>Then by expectation, site number of recurrence <italic>i</italic> (<inline-formula><mml:math id="inf25"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mo>≥</mml:mo><mml:mi mathvariant="bold-italic">i</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>) could be represented by<disp-formula id="equ3"><mml:math id="m3"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi><mml:mo>≥</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>F</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>x</mml:mi><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>Following the same logic, we will have <inline-formula><mml:math id="inf26"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mo>≥</mml:mo><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> as<disp-formula id="equ4"><mml:math id="m4"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi><mml:mo>≥</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>F</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>x</mml:mi><mml:mo>≤</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>Then the expected value for <bold><italic>A<sub>i</sub></italic>_e</bold> is<disp-formula id="equ5"><label>(S3)</label><mml:math id="m5"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>_</mml:mo><mml:mi>e</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi><mml:mo>≥</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi><mml:mo>≥</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>F</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>x</mml:mi><mml:mo>≤</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:mfenced><mml:mo>-</mml:mo><mml:mi>F</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>x</mml:mi><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p><bold><italic>L<sub>A</sub></italic></bold> and <bold><italic>L<sub>S</sub></italic></bold> are missense and synonymous sites, respectively. The calculation procedure is described in methods of the companion paper (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>).</p><p>With <xref ref-type="disp-formula" rid="equ1">Equation S1</xref>, <xref ref-type="disp-formula" rid="equ2">Equation S2</xref>, <xref ref-type="disp-formula" rid="equ5">Equation S3</xref>, we could solve for the expected number of sites with missense mutation recurrence <italic>i</italic>.</p></sec><sec id="s4-3"><title>Survival analysis of <italic>EGFR</italic>-targeted therapy</title><p>The mutation and clinical profiles of 23,253 patients were retrieved from the GENIE project (<xref ref-type="bibr" rid="bib11">Cerami et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">de Bruijn et al., 2023</xref>), with 7216 patients harboring <italic>EGFR</italic> mutations. Survivor months were calculated as the time elapsed between the date of sequencing and the date of the last contact (or day of death). In cases where patients had multiple sequencing reports, the earliest one was selected. For CDN calling, we applied Eq. 10 from the companion paper (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>). With <inline-formula><mml:math id="inf27"><mml:mi>ε</mml:mi><mml:mo>=</mml:mo><mml:mn>0.01</mml:mn></mml:math></inline-formula>, we set the CDN cutoff <italic>i<sup>*</sup></italic> = 14. To mitigate potential biases from other common drivers in lung cancer, patients with indels in exons 19 and 20 of <italic>EGFR</italic>, G12/13 mutations in <italic>KRAS</italic>, V600 mutations in <italic>BRAF</italic>, exon 20 insertions in <italic>HER2</italic>, fusions in <italic>MET</italic>, <italic>ALK</italic>, <italic>ROS1</italic>, <italic>RET</italic>, <italic>NTRK</italic>, and <italic>MET</italic> were filtered out. The final survival analysis was conducted using GraphPad Prism 8.</p></sec><sec id="s4-4"><title>Annotation for noncanonical CDN genes</title><p>We conducted functional annotation and enrichment analysis for newly identified noncanonical CDN genes using four independent databases (Gene Ontology, KEGG, Disease Ontology, and Reactome) with R packages (<italic>clusterProfiler</italic>, <italic>DOSE</italic>, <italic>ReactomePA</italic>). For each analysis, we set a p-value cutoff of 0.05 and a q-value cutoff of 0.2, with p-value adjustment method set to ‘BH’. To explore the connections between noncanonical CDN genes and canonical CDGs, enrichment analyses were performed alongside cancer drivers from IntOGen. Specifically, for enrichment annotations related to cancer hallmarks, the corresponding genes were subjected to manual confirmation using CancerGeneNET (<ext-link ext-link-type="uri" xlink:href="https://signor.uniroma2.it/CancerGeneNet/">https://signor.uniroma2.it/CancerGeneNet/</ext-link>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Validation, Visualization</p></fn><fn fn-type="con" id="con3"><p>Data curation, Validation</p></fn><fn fn-type="con" id="con4"><p>Data curation, Validation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Validation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Validation, Visualization</p></fn><fn fn-type="con" id="con7"><p>Validation, Visualization</p></fn><fn fn-type="con" id="con8"><p>Data curation, Validation</p></fn><fn fn-type="con" id="con9"><p>Resources, Investigation, Project administration</p></fn><fn fn-type="con" id="con10"><p>Resources, Validation, Investigation</p></fn><fn fn-type="con" id="con11"><p>Resources, Supervision, Investigation, Project administration</p></fn><fn fn-type="con" id="con12"><p>Resources, Supervision, Project administration</p></fn><fn fn-type="con" id="con13"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Supervision, Investigation, Project administration</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Supervision, Funding acquisition, Validation, Investigation, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Funding acquisition, Validation, Investigation, Methodology</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-99341-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The scripts for generating the key results of this study and the accompanying paper (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>) are available at <ext-link ext-link-type="uri" xlink:href="https://gitlab.com/ultramicroevo/cdn_v1">GitLab</ext-link> (copy archived at <xref ref-type="bibr" rid="bib68">Zhang, 2024</xref>). Example files for breast cancer analysis have also been included. The complete set of CDNs can be found in Supplementary file 1 of the accompanying paper (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>).</p></sec><ack id="ack"><title>Acknowledgements</title><p>We wish to acknowledge the supports from the First Affiliated Hospital, the Seventh Affiliated Hospital of Sun Yat-sen University, Cancer Center of Clifford Hospital, Jinan University, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, and Guangdong Academy of Medical Sciences, Guangdong Provincial People’s Hospital on the startup of the Cancer Driving Nucleotide (CDN) project. We would like to acknowledge Kunming Institute of Zoology for discussing the ideas of CDN. We thank Weiwei Zhai, Qianfei Wang, and Weini Huang for insightful comments and suggestions. We would also like to acknowledge the American Association for Cancer Research (AACR) and The Cancer Genome Atlas (TCGA) project, which have provided invaluable datasets and resources that have significantly enriched our understanding of cancer biology and improved patient outcomes. This work was supported by the National Natural Science Foundation of China (32150006, 32293193, 32293190, 32370659, and 32200493) to CIW and 82341092 to HJW, the National Key Research and Development Projects of the Ministry of Science and Technology of China (2021YFC0863300, 2021YFC0863400), Guangdong Key Research and Development Program (no. 2022B1111030001), and Guangdong Basic and Applied Basic Research Foundation (no. 2023A1515010016).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anandakrishnan</surname><given-names>R</given-names></name><name><surname>Varghese</surname><given-names>RT</given-names></name><name><surname>Kinney</surname><given-names>NA</given-names></name><name><surname>Garner</surname><given-names>HR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Estimating the number of genetic mutations (hits) required for carcinogenesis based on the distribution of somatic mutations</article-title><source>PLOS Computational Biology</source><volume>15</volume><elocation-id>e1006881</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006881</pub-id><pub-id pub-id-type="pmid">30845172</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>André</surname><given-names>F</given-names></name><name><surname>Arnedos</surname><given-names>M</given-names></name><name><surname>Baras</surname><given-names>AS</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Bedard</surname><given-names>PL</given-names></name><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Bierkens</surname><given-names>M</given-names></name><name><surname>Calvo</surname><given-names>F</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Chakravarty</surname><given-names>D</given-names></name><name><surname>Dang</surname><given-names>KK</given-names></name><name><surname>Davidson</surname><given-names>NE</given-names></name><name><surname>Del Vecchio Fitz</surname><given-names>C</given-names></name><name><surname>Dogan</surname><given-names>S</given-names></name><name><surname>DuBois</surname><given-names>RN</given-names></name><name><surname>Ducar</surname><given-names>MD</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Garcia</surname><given-names>F</given-names></name><name><surname>Gardos</surname><given-names>S</given-names></name><name><surname>Gocke</surname><given-names>CD</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Guinney</surname><given-names>J</given-names></name><name><surname>Heins</surname><given-names>ZJ</given-names></name><name><surname>Hintzen</surname><given-names>S</given-names></name><name><surname>Horlings</surname><given-names>H</given-names></name><name><surname>Hudeček</surname><given-names>J</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name><name><surname>Kamel-Reid</surname><given-names>S</given-names></name><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>Kinyua</surname><given-names>W</given-names></name><name><surname>Kumari</surname><given-names>P</given-names></name><name><surname>Kundra</surname><given-names>R</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Lefebvre</surname><given-names>C</given-names></name><name><surname>LeNoue-Newton</surname><given-names>ML</given-names></name><name><surname>Lepisto</surname><given-names>EM</given-names></name><name><surname>Levy</surname><given-names>MA</given-names></name><name><surname>Lindeman</surname><given-names>NI</given-names></name><name><surname>Lindsay</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>MacConaill</surname><given-names>LE</given-names></name><name><surname>Maurer</surname><given-names>I</given-names></name><name><surname>Maxwell</surname><given-names>DS</given-names></name><name><surname>Meijer</surname><given-names>GA</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Micheel</surname><given-names>CM</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Mills</surname><given-names>G</given-names></name><name><surname>Moore</surname><given-names>ND</given-names></name><name><surname>Nederlof</surname><given-names>PM</given-names></name><name><surname>Omberg</surname><given-names>L</given-names></name><name><surname>Orechia</surname><given-names>JA</given-names></name><name><surname>Park</surname><given-names>BH</given-names></name><name><surname>Pugh</surname><given-names>TJ</given-names></name><name><surname>Reardon</surname><given-names>B</given-names></name><name><surname>Rollins</surname><given-names>BJ</given-names></name><name><surname>Routbort</surname><given-names>MJ</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Schrag</surname><given-names>D</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Shaw</surname><given-names>KRM</given-names></name><name><surname>Shivdasani</surname><given-names>P</given-names></name><name><surname>Siu</surname><given-names>LL</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Sonke</surname><given-names>GS</given-names></name><name><surname>Soria</surname><given-names>JC</given-names></name><name><surname>Sripakdeevong</surname><given-names>P</given-names></name><name><surname>Stickle</surname><given-names>NH</given-names></name><name><surname>Stricker</surname><given-names>TP</given-names></name><name><surname>Sweeney</surname><given-names>SM</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>ten Hoeve</surname><given-names>JJ</given-names></name><name><surname>Thomas</surname><given-names>SB</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Van ’T Veer</surname><given-names>LJ</given-names></name><name><surname>van de Velde</surname><given-names>T</given-names></name><name><surname>van Tinteren</surname><given-names>H</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Virtanen</surname><given-names>C</given-names></name><name><surname>Voest</surname><given-names>EE</given-names></name><name><surname>Wang</surname><given-names>LL</given-names></name><name><surname>Wathoo</surname><given-names>C</given-names></name><name><surname>Watt</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>TV</given-names></name><name><surname>Yu</surname><given-names>E</given-names></name><name><surname>Zehir</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><collab>The AACR Project GENIE Consortium</collab><collab>The AACR Project GENIE Consortium</collab></person-group><year iso-8601-date="2017">2017</year><article-title>AACR project genie: powering precision medicine through an international consortium</article-title><source>Cancer Discovery</source><volume>7</volume><fpage>818</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0151</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>P</given-names></name><name><surname>Doll</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1954">1954</year><article-title>The age distribution of cancer and a multi-stage theory of carcinogenesis</article-title><source>British Journal of Cancer</source><volume>8</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/bjc.1954.1</pub-id><pub-id pub-id-type="pmid">13172380</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnedo-Pac</surname><given-names>C</given-names></name><name><surname>Mularoni</surname><given-names>L</given-names></name><name><surname>Muiños</surname><given-names>F</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>OncodriveCLUSTL: a sequence-based clustering method to identify cancer drivers</article-title><source>Bioinformatics</source><volume>35</volume><fpage>4788</fpage><lpage>4790</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btz501</pub-id><pub-id pub-id-type="pmid">31228182</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>MH</given-names></name><name><surname>Tokheim</surname><given-names>C</given-names></name><name><surname>Porta-Pardo</surname><given-names>E</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Bertrand</surname><given-names>D</given-names></name><name><surname>Weerasinghe</surname><given-names>A</given-names></name><name><surname>Colaprico</surname><given-names>A</given-names></name><name><surname>Wendl</surname><given-names>MC</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Reardon</surname><given-names>B</given-names></name><name><surname>Ng</surname><given-names>PKS</given-names></name><name><surname>Jeong</surname><given-names>KJ</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>EM</given-names></name><name><surname>Mularoni</surname><given-names>L</given-names></name><name><surname>Rubio-Perez</surname><given-names>C</given-names></name><name><surname>Nagarajan</surname><given-names>N</given-names></name><name><surname>Cortés-Ciriano</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>DC</given-names></name><name><surname>Liang</surname><given-names>WW</given-names></name><name><surname>Hess</surname><given-names>JM</given-names></name><name><surname>Yellapantula</surname><given-names>VD</given-names></name><name><surname>Tamborero</surname><given-names>D</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name><surname>Suphavilai</surname><given-names>C</given-names></name><name><surname>Ko</surname><given-names>JY</given-names></name><name><surname>Khurana</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>PJ</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><collab>MC3 Working Group</collab><collab>Cancer Genome Atlas Research Network</collab><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Godzik</surname><given-names>A</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N</given-names></name><name><surname>Stuart</surname><given-names>J</given-names></name><name><surname>Wheeler</surname><given-names>D</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Karchin</surname><given-names>R</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Comprehensive characterization of cancer driver genes and mutations</article-title><source>Cell</source><volume>173</volume><fpage>371</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.02.060</pub-id><pub-id pub-id-type="pmid">29625053</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belikov</surname><given-names>AV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The number of key carcinogenic events can be predicted from cancer incidence</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>12170</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-12448-7</pub-id><pub-id pub-id-type="pmid">28939880</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bian</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Integrative single-cell multiomics analyses dissect molecular signatures of intratumoral heterogeneities and differentiation states of human gastric cancer</article-title><source>National Science Review</source><volume>10</volume><elocation-id>wad094</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwad094</pub-id><pub-id pub-id-type="pmid">37347037</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozic</surname><given-names>I</given-names></name><name><surname>Antal</surname><given-names>T</given-names></name><name><surname>Ohtsuki</surname><given-names>H</given-names></name><name><surname>Carter</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Karchin</surname><given-names>R</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Accumulation of driver and passenger mutations during tumor progression</article-title><source>PNAS</source><volume>107</volume><fpage>18545</fpage><lpage>18550</lpage><pub-id pub-id-type="doi">10.1073/pnas.1010978107</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Korbel</surname><given-names>JO</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name><name><surname>Jennings</surname><given-names>JL</given-names></name><name><surname>Stein</surname><given-names>LD</given-names></name><name><surname>Perry</surname><given-names>MD</given-names></name><name><surname>Nahal-Bose</surname><given-names>HK</given-names></name><name><surname>Ouellette</surname><given-names>BFF</given-names></name><name><surname>Li</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pan-cancer analysis of whole genomes</article-title><source>Nature</source><volume>578</volume><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1969-6</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cun</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Hoh</surname><given-names>BP</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Kong</surname><given-names>HZ</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>SC</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Nie</surname><given-names>Q</given-names></name><name><surname>Qiu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>T</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>SC</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>CC</given-names></name><name><surname>Wang</surname><given-names>GD</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Ye</surname><given-names>YN</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhai</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>YP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Was Wuhan the early epicenter of the COVID-19 pandemic?-A critique</article-title><source>National Science Review</source><volume>10</volume><elocation-id>wac287</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwac287</pub-id><pub-id pub-id-type="pmid">37089192</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>CJ</given-names></name><name><surname>Heuer</surname><given-names>ML</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title><source>Cancer Discovery</source><volume>2</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Lan</surname><given-names>A</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Molecular evolution in large steps-codon substitutions under positive selection</article-title><source>Molecular Biology and Evolution</source><volume>36</volume><fpage>1862</fpage><lpage>1873</lpage><pub-id pub-id-type="doi">10.1093/molbev/msz108</pub-id><pub-id pub-id-type="pmid">31077325</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Lan</surname><given-names>A</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Molecular evolution in small steps under prevailing negative selection: a nearly universal rule of codon substitution</article-title><source>Genome Biology and Evolution</source><volume>11</volume><fpage>2702</fpage><lpage>2712</lpage><pub-id pub-id-type="doi">10.1093/gbe/evz192</pub-id><pub-id pub-id-type="pmid">31504473</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Ruan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Zapata</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>CI</given-names></name><name><surname>Lan</surname><given-names>P</given-names></name><name><surname>Wen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>Very large hidden genetic diversity in one single tumor: evidence for tumors-in-tumor</article-title><source>National Science Review</source><volume>9</volume><elocation-id>wac250</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwac250</pub-id><pub-id pub-id-type="pmid">36694802</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>CI</given-names></name><name><surname>He</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Two decades of suspect evidence for adaptive molecular evolution-negative selection confounding positive-selection signals</article-title><source>National Science Review</source><volume>9</volume><elocation-id>wab217</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwab217</pub-id><pub-id pub-id-type="pmid">35663241</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>NJ</given-names></name><name><surname>Lavery</surname><given-names>JA</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>de Bruijn</surname><given-names>I</given-names></name><name><surname>Jee</surname><given-names>J</given-names></name><name><surname>Tran</surname><given-names>TN</given-names></name><name><surname>Rizvi</surname><given-names>H</given-names></name><name><surname>Arbour</surname><given-names>KC</given-names></name><name><surname>Whiting</surname><given-names>K</given-names></name><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Hellmann</surname><given-names>M</given-names></name><name><surname>Bedard</surname><given-names>PL</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Leighl</surname><given-names>N</given-names></name><name><surname>LeNoue-Newton</surname><given-names>M</given-names></name><name><surname>Micheel</surname><given-names>C</given-names></name><name><surname>Warner</surname><given-names>JL</given-names></name><name><surname>Ginsberg</surname><given-names>MS</given-names></name><name><surname>Plodkowski</surname><given-names>A</given-names></name><name><surname>Girshman</surname><given-names>J</given-names></name><name><surname>Sawan</surname><given-names>P</given-names></name><name><surname>Pillai</surname><given-names>S</given-names></name><name><surname>Sweeney</surname><given-names>SM</given-names></name><name><surname>Kehl</surname><given-names>KL</given-names></name><name><surname>Panageas</surname><given-names>KS</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Schrag</surname><given-names>D</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><collab>on behalf of the AACR GENIE BPC Core Team</collab></person-group><year iso-8601-date="2023">2023</year><article-title>The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non–small cell lung cancer</article-title><source>Clinical Cancer Research</source><volume>29</volume><fpage>3418</fpage><lpage>3428</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-0580</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danesi</surname><given-names>R</given-names></name><name><surname>Fogli</surname><given-names>S</given-names></name><name><surname>Indraccolo</surname><given-names>S</given-names></name><name><surname>Del Re</surname><given-names>M</given-names></name><name><surname>Dei Tos</surname><given-names>AP</given-names></name><name><surname>Leoncini</surname><given-names>L</given-names></name><name><surname>Antonuzzo</surname><given-names>L</given-names></name><name><surname>Bonanno</surname><given-names>L</given-names></name><name><surname>Guarneri</surname><given-names>V</given-names></name><name><surname>Pierini</surname><given-names>A</given-names></name><name><surname>Amunni</surname><given-names>G</given-names></name><name><surname>Conte</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards</article-title><source>ESMO Open</source><volume>6</volume><elocation-id>100040</elocation-id><pub-id pub-id-type="doi">10.1016/j.esmoop.2020.100040</pub-id><pub-id pub-id-type="pmid">33540286</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>CV</given-names></name><name><surname>Reddy</surname><given-names>EP</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Soucek</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Drugging the “undruggable” cancer targets</article-title><source>Nature Reviews. Cancer</source><volume>17</volume><fpage>502</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.36</pub-id><pub-id pub-id-type="pmid">28643779</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bruijn</surname><given-names>I</given-names></name><name><surname>Kundra</surname><given-names>R</given-names></name><name><surname>Mastrogiacomo</surname><given-names>B</given-names></name><name><surname>Tran</surname><given-names>TN</given-names></name><name><surname>Sikina</surname><given-names>L</given-names></name><name><surname>Mazor</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ochoa</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Lai</surname><given-names>B</given-names></name><name><surname>Abeshouse</surname><given-names>A</given-names></name><name><surname>Baiceanu</surname><given-names>D</given-names></name><name><surname>Ciftci</surname><given-names>E</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Dufilie</surname><given-names>A</given-names></name><name><surname>Erkoc</surname><given-names>Z</given-names></name><name><surname>Garcia Lara</surname><given-names>E</given-names></name><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Gross</surname><given-names>B</given-names></name><name><surname>Haynes</surname><given-names>C</given-names></name><name><surname>Heath</surname><given-names>A</given-names></name><name><surname>Higgins</surname><given-names>D</given-names></name><name><surname>Jagannathan</surname><given-names>P</given-names></name><name><surname>Kalletla</surname><given-names>K</given-names></name><name><surname>Kumari</surname><given-names>P</given-names></name><name><surname>Lindsay</surname><given-names>J</given-names></name><name><surname>Lisman</surname><given-names>A</given-names></name><name><surname>Leenknegt</surname><given-names>B</given-names></name><name><surname>Lukasse</surname><given-names>P</given-names></name><name><surname>Madela</surname><given-names>D</given-names></name><name><surname>Madupuri</surname><given-names>R</given-names></name><name><surname>van Nierop</surname><given-names>P</given-names></name><name><surname>Plantalech</surname><given-names>O</given-names></name><name><surname>Quach</surname><given-names>J</given-names></name><name><surname>Resnick</surname><given-names>AC</given-names></name><name><surname>Rodenburg</surname><given-names>SYA</given-names></name><name><surname>Satravada</surname><given-names>BA</given-names></name><name><surname>Schaeffer</surname><given-names>F</given-names></name><name><surname>Sheridan</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><name><surname>Sirohi</surname><given-names>R</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>van Hagen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Rusk</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Lavery</surname><given-names>JA</given-names></name><name><surname>Panageas</surname><given-names>KS</given-names></name><name><surname>Rudolph</surname><given-names>JE</given-names></name><name><surname>LeNoue-Newton</surname><given-names>ML</given-names></name><name><surname>Warner</surname><given-names>JL</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Hunter-Zinck</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>TV</given-names></name><name><surname>Pilai</surname><given-names>S</given-names></name><name><surname>Nichols</surname><given-names>C</given-names></name><name><surname>Gardos</surname><given-names>SM</given-names></name><name><surname>Philip</surname><given-names>J</given-names></name><name><surname>Kehl</surname><given-names>KL</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Schrag</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Fiandalo</surname><given-names>MV</given-names></name><name><surname>Sweeney</surname><given-names>SM</given-names></name><name><surname>Pugh</surname><given-names>TJ</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><collab>AACR Project GENIE BPC Core Team, AACR Project GENIE Consortium</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE biopharma collaborative in cBioPortal</article-title><source>Cancer Research</source><volume>83</volume><fpage>3861</fpage><lpage>3867</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-23-0816</pub-id><pub-id pub-id-type="pmid">37668528</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Xing</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mutation signatures inform the natural host of SARS-CoV-2</article-title><source>National Science Review</source><volume>9</volume><elocation-id>wab220</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwab220</pub-id><pub-id pub-id-type="pmid">35211321</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grantham</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1974">1974</year><article-title>Amino acid difference formula to help explain protein evolution</article-title><source>Science</source><volume>185</volume><fpage>862</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1126/science.185.4154.862</pub-id><pub-id pub-id-type="pmid">4843792</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The hallmarks of cancer</article-title><source>Cell</source><volume>100</volume><fpage>57</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81683-9</pub-id><pub-id pub-id-type="pmid">10647931</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Hallmarks of cancer: new dimensions</article-title><source>Cancer Discovery</source><volume>12</volume><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-1059</pub-id><pub-id pub-id-type="pmid">35022204</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodis</surname><given-names>E</given-names></name><name><surname>Torlai Triglia</surname><given-names>E</given-names></name><name><surname>Kwon</surname><given-names>JYH</given-names></name><name><surname>Biancalani</surname><given-names>T</given-names></name><name><surname>Zakka</surname><given-names>LR</given-names></name><name><surname>Parkar</surname><given-names>S</given-names></name><name><surname>Hütter</surname><given-names>J-C</given-names></name><name><surname>Buffoni</surname><given-names>L</given-names></name><name><surname>Delorey</surname><given-names>TM</given-names></name><name><surname>Phillips</surname><given-names>D</given-names></name><name><surname>Dionne</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>LT</given-names></name><name><surname>Schapiro</surname><given-names>D</given-names></name><name><surname>Maliga</surname><given-names>Z</given-names></name><name><surname>Jacobson</surname><given-names>CA</given-names></name><name><surname>Hendel</surname><given-names>A</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Mihm</surname><given-names>MC</given-names><suffix>Jr</suffix></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment</article-title><source>Science</source><volume>376</volume><elocation-id>eabi8175</elocation-id><pub-id pub-id-type="doi">10.1126/science.abi8175</pub-id><pub-id pub-id-type="pmid">35482859</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>McLellan</surname><given-names>MD</given-names></name><name><surname>Vandin</surname><given-names>F</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Niu</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>McMichael</surname><given-names>JF</given-names></name><name><surname>Wyczalkowski</surname><given-names>MA</given-names></name><name><surname>Leiserson</surname><given-names>MDM</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Welch</surname><given-names>JS</given-names></name><name><surname>Walter</surname><given-names>MJ</given-names></name><name><surname>Wendl</surname><given-names>MC</given-names></name><name><surname>Ley</surname><given-names>TJ</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational landscape and significance across 12 major cancer types</article-title><source>Nature</source><volume>502</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nature12634</pub-id><pub-id pub-id-type="pmid">24132290</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagou</surname><given-names>V</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Ulrich</surname><given-names>A</given-names></name><name><surname>Zudina</surname><given-names>L</given-names></name><name><surname>González</surname><given-names>KSG</given-names></name><name><surname>Balkhiyarova</surname><given-names>Z</given-names></name><name><surname>Faggian</surname><given-names>A</given-names></name><name><surname>Maina</surname><given-names>JG</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Todorov</surname><given-names>PV</given-names></name><name><surname>Sharapov</surname><given-names>S</given-names></name><name><surname>David</surname><given-names>A</given-names></name><name><surname>Marullo</surname><given-names>L</given-names></name><name><surname>Mägi</surname><given-names>R</given-names></name><name><surname>Rujan</surname><given-names>R-M</given-names></name><name><surname>Ahlqvist</surname><given-names>E</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>Η</given-names></name><name><surname>Εvangelou</surname><given-names>Ε</given-names></name><name><surname>Benyamin</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>RA</given-names></name><name><surname>Isaacs</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>JH</given-names></name><name><surname>Willems</surname><given-names>SM</given-names></name><name><surname>Johnson</surname><given-names>T</given-names></name><name><surname>Gieger</surname><given-names>C</given-names></name><name><surname>Grallert</surname><given-names>H</given-names></name><name><surname>Meisinger</surname><given-names>C</given-names></name><name><surname>Müller-Nurasyid</surname><given-names>M</given-names></name><name><surname>Strawbridge</surname><given-names>RJ</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name><name><surname>Rybin</surname><given-names>D</given-names></name><name><surname>Albrecht</surname><given-names>E</given-names></name><name><surname>Jackson</surname><given-names>AU</given-names></name><name><surname>Stringham</surname><given-names>HM</given-names></name><name><surname>Corrêa</surname><given-names>IR</given-names><suffix>Jr</suffix></name><name><surname>Farber-Eger</surname><given-names>E</given-names></name><name><surname>Steinthorsdottir</surname><given-names>V</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>Munroe</surname><given-names>PB</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name><name><surname>Schmidberger</surname><given-names>J</given-names></name><name><surname>Holmen</surname><given-names>O</given-names></name><name><surname>Thorand</surname><given-names>B</given-names></name><name><surname>Hveem</surname><given-names>K</given-names></name><name><surname>Wilsgaard</surname><given-names>T</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><collab>GWA-PA Consortium</collab><name><surname>Shmeliov</surname><given-names>A</given-names></name><name><surname>den Hoed</surname><given-names>M</given-names></name><name><surname>Loos</surname><given-names>RJF</given-names></name><name><surname>Kratzer</surname><given-names>W</given-names></name><name><surname>Haenle</surname><given-names>M</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name><name><surname>Boehm</surname><given-names>BO</given-names></name><name><surname>Tan</surname><given-names>TM</given-names></name><name><surname>Tomas</surname><given-names>A</given-names></name><name><surname>Salem</surname><given-names>V</given-names></name><name><surname>Barroso</surname><given-names>I</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Florez</surname><given-names>JC</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name><name><surname>Watkins</surname><given-names>H</given-names></name><name><surname>Njølstad</surname><given-names>I</given-names></name><name><surname>Wichmann</surname><given-names>H-E</given-names></name><name><surname>Caulfield</surname><given-names>MJ</given-names></name><name><surname>Khaw</surname><given-names>K-T</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><name><surname>Langenberg</surname><given-names>C</given-names></name><name><surname>Whitfield</surname><given-names>JB</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name><name><surname>Montgomery</surname><given-names>G</given-names></name><name><surname>Scapoli</surname><given-names>C</given-names></name><name><surname>Tzoulaki</surname><given-names>I</given-names></name><name><surname>Elliott</surname><given-names>P</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Brittain</surname><given-names>EL</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name><name><surname>Sexton</surname><given-names>PM</given-names></name><name><surname>Wootten</surname><given-names>D</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name><name><surname>Dupuis</surname><given-names>J</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Deganutti</surname><given-names>G</given-names></name><name><surname>Demirkan</surname><given-names>A</given-names></name><name><surname>Pers</surname><given-names>TH</given-names></name><name><surname>Reynolds</surname><given-names>CA</given-names></name><name><surname>Aulchenko</surname><given-names>YS</given-names></name><name><surname>Kaakinen</surname><given-names>MA</given-names></name><name><surname>Jones</surname><given-names>B</given-names></name><name><surname>Prokopenko</surname><given-names>I</given-names></name><collab>Meta-Analysis of Glucose and Insulin-Related Traits Consortium (MAGIC)</collab></person-group><year iso-8601-date="2023">2023</year><article-title>GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification</article-title><source>Nature Genetics</source><volume>55</volume><fpage>1448</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1038/s41588-023-01462-3</pub-id><pub-id pub-id-type="pmid">37679419</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Stojanov</surname><given-names>P</given-names></name><name><surname>Polak</surname><given-names>P</given-names></name><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Sivachenko</surname><given-names>A</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Stewart</surname><given-names>C</given-names></name><name><surname>Mermel</surname><given-names>CH</given-names></name><name><surname>Roberts</surname><given-names>SA</given-names></name><name><surname>Kiezun</surname><given-names>A</given-names></name><name><surname>Hammerman</surname><given-names>PS</given-names></name><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Drier</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Ramos</surname><given-names>AH</given-names></name><name><surname>Pugh</surname><given-names>TJ</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Helman</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Ambrogio</surname><given-names>L</given-names></name><name><surname>Nickerson</surname><given-names>E</given-names></name><name><surname>Shefler</surname><given-names>E</given-names></name><name><surname>Cortés</surname><given-names>ML</given-names></name><name><surname>Auclair</surname><given-names>D</given-names></name><name><surname>Saksena</surname><given-names>G</given-names></name><name><surname>Voet</surname><given-names>D</given-names></name><name><surname>Noble</surname><given-names>M</given-names></name><name><surname>DiCara</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Lichtenstein</surname><given-names>L</given-names></name><name><surname>Heiman</surname><given-names>DI</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>B</given-names></name><name><surname>Hodis</surname><given-names>E</given-names></name><name><surname>Baca</surname><given-names>S</given-names></name><name><surname>Dulak</surname><given-names>AM</given-names></name><name><surname>Lohr</surname><given-names>J</given-names></name><name><surname>Landau</surname><given-names>D-A</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Melendez-Zajgla</surname><given-names>J</given-names></name><name><surname>Hidalgo-Miranda</surname><given-names>A</given-names></name><name><surname>Koren</surname><given-names>A</given-names></name><name><surname>McCarroll</surname><given-names>SA</given-names></name><name><surname>Mora</surname><given-names>J</given-names></name><name><surname>Crompton</surname><given-names>B</given-names></name><name><surname>Onofrio</surname><given-names>R</given-names></name><name><surname>Parkin</surname><given-names>M</given-names></name><name><surname>Winckler</surname><given-names>W</given-names></name><name><surname>Ardlie</surname><given-names>K</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Roberts</surname><given-names>CWM</given-names></name><name><surname>Biegel</surname><given-names>JA</given-names></name><name><surname>Stegmaier</surname><given-names>K</given-names></name><name><surname>Bass</surname><given-names>AJ</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Gordenin</surname><given-names>DA</given-names></name><name><surname>Sunyaev</surname><given-names>S</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational heterogeneity in cancer and the search for new cancer-associated genes</article-title><source>Nature</source><volume>499</volume><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nature12213</pub-id><pub-id pub-id-type="pmid">23770567</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>WH</given-names></name><name><surname>Wu</surname><given-names>CI</given-names></name><name><surname>Luo</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>A new method for estimating synonymous and nonsynonymous rates of nucleotide substitution considering the relative likelihood of nucleotide and codon changes</article-title><source>Molecular Biology and Evolution</source><volume>2</volume><fpage>150</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.molbev.a040343</pub-id><pub-id pub-id-type="pmid">3916709</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Zhan</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Maimaitiyiming</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Su</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Naranmandura</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>KJ</given-names></name><name><surname>Min</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Björklund</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>PF</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>YTHDF2-mediated regulations bifurcate BHPF-induced programmed cell deaths</article-title><source>National Science Review</source><volume>10</volume><elocation-id>wad227</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwad227</pub-id><pub-id pub-id-type="pmid">38152479</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Jia</surname><given-names>N</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pan-cancer analysis on the role of PIK3R1 and PIK3R2 in human tumors</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>5924</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-09889-0</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martincorena</surname><given-names>I</given-names></name><name><surname>Raine</surname><given-names>KM</given-names></name><name><surname>Gerstung</surname><given-names>M</given-names></name><name><surname>Dawson</surname><given-names>KJ</given-names></name><name><surname>Haase</surname><given-names>K</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Universal patterns of selection in cancer and somatic tissues</article-title><source>Cell</source><volume>171</volume><fpage>1029</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.042</pub-id><pub-id pub-id-type="pmid">29056346</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez-Jiménez</surname><given-names>F</given-names></name><name><surname>Muiños</surname><given-names>F</given-names></name><name><surname>Sentís</surname><given-names>I</given-names></name><name><surname>Deu-Pons</surname><given-names>J</given-names></name><name><surname>Reyes-Salazar</surname><given-names>I</given-names></name><name><surname>Arnedo-Pac</surname><given-names>C</given-names></name><name><surname>Mularoni</surname><given-names>L</given-names></name><name><surname>Pich</surname><given-names>O</given-names></name><name><surname>Bonet</surname><given-names>J</given-names></name><name><surname>Kranas</surname><given-names>H</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A compendium of mutational cancer driver genes</article-title><source>Nature Reviews. Cancer</source><volume>20</volume><fpage>555</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1038/s41568-020-0290-x</pub-id><pub-id pub-id-type="pmid">32778778</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Kames</surname><given-names>J</given-names></name><name><surname>Bar</surname><given-names>H</given-names></name><name><surname>Komar</surname><given-names>AA</given-names></name><name><surname>Alexaki</surname><given-names>A</given-names></name><name><surname>Ibla</surname><given-names>J</given-names></name><name><surname>Hunt</surname><given-names>RC</given-names></name><name><surname>Santana-Quintero</surname><given-names>LV</given-names></name><name><surname>Golikov</surname><given-names>A</given-names></name><name><surname>DiCuccio</surname><given-names>M</given-names></name><name><surname>Kimchi-Sarfaty</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Distinct signatures of codon and codon pair usage in 32 primary tumor types in the novel database CancerCoCoPUTs for cancer-specific codon usage</article-title><source>Genome Medicine</source><volume>13</volume><elocation-id>122</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-021-00935-6</pub-id><pub-id pub-id-type="pmid">34321100</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mularoni</surname><given-names>L</given-names></name><name><surname>Sabarinathan</surname><given-names>R</given-names></name><name><surname>Deu-Pons</surname><given-names>J</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name><surname>López-Bigas</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations</article-title><source>Genome Biology</source><volume>17</volume><elocation-id>128</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-0994-0</pub-id><pub-id pub-id-type="pmid">27311963</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najumudeen</surname><given-names>AK</given-names></name><name><surname>Ceteci</surname><given-names>F</given-names></name><name><surname>Fey</surname><given-names>SK</given-names></name><name><surname>Hamm</surname><given-names>G</given-names></name><name><surname>Steven</surname><given-names>RT</given-names></name><name><surname>Hall</surname><given-names>H</given-names></name><name><surname>Nikula</surname><given-names>CJ</given-names></name><name><surname>Dexter</surname><given-names>A</given-names></name><name><surname>Murta</surname><given-names>T</given-names></name><name><surname>Race</surname><given-names>AM</given-names></name><name><surname>Sumpton</surname><given-names>D</given-names></name><name><surname>Vlahov</surname><given-names>N</given-names></name><name><surname>Gay</surname><given-names>DM</given-names></name><name><surname>Knight</surname><given-names>JRP</given-names></name><name><surname>Jackstadt</surname><given-names>R</given-names></name><name><surname>Leach</surname><given-names>JDG</given-names></name><name><surname>Ridgway</surname><given-names>RA</given-names></name><name><surname>Johnson</surname><given-names>ER</given-names></name><name><surname>Nixon</surname><given-names>C</given-names></name><name><surname>Hedley</surname><given-names>A</given-names></name><name><surname>Gilroy</surname><given-names>K</given-names></name><name><surname>Clark</surname><given-names>W</given-names></name><name><surname>Malla</surname><given-names>SB</given-names></name><name><surname>Dunne</surname><given-names>PD</given-names></name><name><surname>Rodriguez-Blanco</surname><given-names>G</given-names></name><name><surname>Critchlow</surname><given-names>SE</given-names></name><name><surname>Mrowinska</surname><given-names>A</given-names></name><name><surname>Malviya</surname><given-names>G</given-names></name><name><surname>Solovyev</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>G</given-names></name><name><surname>Lewis</surname><given-names>DY</given-names></name><name><surname>Mackay</surname><given-names>GM</given-names></name><name><surname>Strathdee</surname><given-names>D</given-names></name><name><surname>Tardito</surname><given-names>S</given-names></name><name><surname>Gottlieb</surname><given-names>E</given-names></name><collab>CRUK Rosetta Grand Challenge Consortium</collab><name><surname>Takats</surname><given-names>Z</given-names></name><name><surname>Barry</surname><given-names>ST</given-names></name><name><surname>Goodwin</surname><given-names>RJA</given-names></name><name><surname>Bunch</surname><given-names>J</given-names></name><name><surname>Bushell</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>AD</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer</article-title><source>Nature Genetics</source><volume>53</volume><fpage>16</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-00753-3</pub-id><pub-id pub-id-type="pmid">33414552</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nei</surname><given-names>M</given-names></name><name><surname>Gojobori</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions</article-title><source>Molecular Biology and Evolution</source><volume>3</volume><fpage>418</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.molbev.a040410</pub-id><pub-id pub-id-type="pmid">3444411</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Greenman</surname><given-names>CD</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Hinton</surname><given-names>J</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Stebbings</surname><given-names>LA</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Leroy</surname><given-names>C</given-names></name><name><surname>Ramakrishna</surname><given-names>M</given-names></name><name><surname>Rance</surname><given-names>R</given-names></name><name><surname>Lau</surname><given-names>KW</given-names></name><name><surname>Mudie</surname><given-names>LJ</given-names></name><name><surname>Varela</surname><given-names>I</given-names></name><name><surname>McBride</surname><given-names>DJ</given-names></name><name><surname>Bignell</surname><given-names>GR</given-names></name><name><surname>Cooke</surname><given-names>SL</given-names></name><name><surname>Shlien</surname><given-names>A</given-names></name><name><surname>Gamble</surname><given-names>J</given-names></name><name><surname>Whitmore</surname><given-names>I</given-names></name><name><surname>Maddison</surname><given-names>M</given-names></name><name><surname>Tarpey</surname><given-names>PS</given-names></name><name><surname>Davies</surname><given-names>HR</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Stephens</surname><given-names>PJ</given-names></name><name><surname>McLaren</surname><given-names>S</given-names></name><name><surname>Butler</surname><given-names>AP</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Jönsson</surname><given-names>G</given-names></name><name><surname>Garber</surname><given-names>JE</given-names></name><name><surname>Silver</surname><given-names>D</given-names></name><name><surname>Miron</surname><given-names>P</given-names></name><name><surname>Fatima</surname><given-names>A</given-names></name><name><surname>Boyault</surname><given-names>S</given-names></name><name><surname>Langerød</surname><given-names>A</given-names></name><name><surname>Tutt</surname><given-names>A</given-names></name><name><surname>Martens</surname><given-names>JWM</given-names></name><name><surname>Aparicio</surname><given-names>SAJR</given-names></name><name><surname>Borg</surname><given-names>Å</given-names></name><name><surname>Salomon</surname><given-names>AV</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Børresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Neuberger</surname><given-names>MS</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><collab>Breast Cancer Working Group of the International Cancer Genome Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Mutational processes molding the genomes of 21 breast cancers</article-title><source>Cell</source><volume>149</volume><fpage>979</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.04.024</pub-id><pub-id pub-id-type="pmid">22608084</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortmann</surname><given-names>CA</given-names></name><name><surname>Kent</surname><given-names>DG</given-names></name><name><surname>Nangalia</surname><given-names>J</given-names></name><name><surname>Silber</surname><given-names>Y</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Grinfeld</surname><given-names>J</given-names></name><name><surname>Baxter</surname><given-names>EJ</given-names></name><name><surname>Massie</surname><given-names>CE</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Menon</surname><given-names>S</given-names></name><name><surname>Godfrey</surname><given-names>AL</given-names></name><name><surname>Dimitropoulou</surname><given-names>D</given-names></name><name><surname>Guglielmelli</surname><given-names>P</given-names></name><name><surname>Bellosillo</surname><given-names>B</given-names></name><name><surname>Besses</surname><given-names>C</given-names></name><name><surname>Döhner</surname><given-names>K</given-names></name><name><surname>Harrison</surname><given-names>CN</given-names></name><name><surname>Vassiliou</surname><given-names>GS</given-names></name><name><surname>Vannucchi</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Effect of mutation order on myeloproliferative neoplasms</article-title><source>The New England Journal of Medicine</source><volume>372</volume><fpage>601</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1412098</pub-id><pub-id pub-id-type="pmid">25671252</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Ning</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Mamatyusupu</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Genomic diversity and post-admixture adaptation in the Uyghurs</article-title><source>National Science Review</source><volume>9</volume><elocation-id>wab124</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwab124</pub-id><pub-id pub-id-type="pmid">35350227</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passaro</surname><given-names>A</given-names></name><name><surname>Leighl</surname><given-names>N</given-names></name><name><surname>Blackhall</surname><given-names>F</given-names></name><name><surname>Popat</surname><given-names>S</given-names></name><name><surname>Kerr</surname><given-names>K</given-names></name><name><surname>Ahn</surname><given-names>MJ</given-names></name><name><surname>Arcila</surname><given-names>ME</given-names></name><name><surname>Arrieta</surname><given-names>O</given-names></name><name><surname>Planchard</surname><given-names>D</given-names></name><name><surname>de Marinis</surname><given-names>F</given-names></name><name><surname>Dingemans</surname><given-names>AM</given-names></name><name><surname>Dziadziuszko</surname><given-names>R</given-names></name><name><surname>Faivre-Finn</surname><given-names>C</given-names></name><name><surname>Feldman</surname><given-names>J</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Curigliano</surname><given-names>G</given-names></name><name><surname>Herbst</surname><given-names>R</given-names></name><name><surname>Jänne</surname><given-names>PA</given-names></name><name><surname>John</surname><given-names>T</given-names></name><name><surname>Mitsudomi</surname><given-names>T</given-names></name><name><surname>Mok</surname><given-names>T</given-names></name><name><surname>Normanno</surname><given-names>N</given-names></name><name><surname>Paz-Ares</surname><given-names>L</given-names></name><name><surname>Ramalingam</surname><given-names>S</given-names></name><name><surname>Sequist</surname><given-names>L</given-names></name><name><surname>Vansteenkiste</surname><given-names>J</given-names></name><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Wolf</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Yang</surname><given-names>SR</given-names></name><name><surname>Yang</surname><given-names>JCH</given-names></name><name><surname>Yatabe</surname><given-names>Y</given-names></name><name><surname>Pentheroudakis</surname><given-names>G</given-names></name><name><surname>Peters</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer</article-title><source>Annals of Oncology</source><volume>33</volume><fpage>466</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.02.003</pub-id><pub-id pub-id-type="pmid">35176458</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porta-Pardo</surname><given-names>E</given-names></name><name><surname>Godzik</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>e-Driver: a novel method to identify protein regions driving cancer</article-title><source>Bioinformatics</source><volume>30</volume><fpage>3109</fpage><lpage>3114</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu499</pub-id><pub-id pub-id-type="pmid">25064568</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reimand</surname><given-names>J</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers</article-title><source>Molecular Systems Biology</source><volume>9</volume><elocation-id>637</elocation-id><pub-id pub-id-type="doi">10.1038/msb.2012.68</pub-id><pub-id pub-id-type="pmid">23340843</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>SA</given-names></name><name><surname>Gordenin</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hypermutation in human cancer genomes: footprints and mechanisms</article-title><source>Nature Reviews. Cancer</source><volume>14</volume><fpage>786</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1038/nrc3816</pub-id><pub-id pub-id-type="pmid">25568919</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>H</given-names></name><name><surname>Hou</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>YP</given-names></name><name><surname>Wu</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The twin-beginnings of COVID-19 in Asia and Europe-one prevails quickly</article-title><source>National Science Review</source><volume>9</volume><elocation-id>wab223</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwab223</pub-id><pub-id pub-id-type="pmid">35497643</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>H</given-names></name><name><surname>Hou</surname><given-names>M</given-names></name><name><surname>Zhai</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>On the epicenter of COVID-19 and the origin of the pandemic strain</article-title><source>National Science Review</source><volume>10</volume><elocation-id>wac286</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwac286</pub-id><pub-id pub-id-type="pmid">37089190</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>MA</given-names></name><name><surname>Yaari</surname><given-names>AU</given-names></name><name><surname>Priebe</surname><given-names>O</given-names></name><name><surname>Dietlein</surname><given-names>F</given-names></name><name><surname>Loh</surname><given-names>PR</given-names></name><name><surname>Berger</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Genome-wide mapping of somatic mutation rates uncovers drivers of cancer</article-title><source>Nature Biotechnology</source><volume>40</volume><fpage>1634</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1038/s41587-022-01353-8</pub-id><pub-id pub-id-type="pmid">35726091</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sondka</surname><given-names>Z</given-names></name><name><surname>Bamford</surname><given-names>S</given-names></name><name><surname>Cole</surname><given-names>CG</given-names></name><name><surname>Ward</surname><given-names>SA</given-names></name><name><surname>Dunham</surname><given-names>I</given-names></name><name><surname>Forbes</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers</article-title><source>Nature Reviews. Cancer</source><volume>18</volume><fpage>696</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1038/s41568-018-0060-1</pub-id><pub-id pub-id-type="pmid">30293088</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Maslov</surname><given-names>AY</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Vijg</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SomaMutDB: a database of somatic mutations in normal human tissues</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>D1100</fpage><lpage>D1108</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab914</pub-id><pub-id pub-id-type="pmid">34634815</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Hatzikotoulas</surname><given-names>K</given-names></name><name><surname>Southam</surname><given-names>L</given-names></name><name><surname>Taylor</surname><given-names>HJ</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Lorenz</surname><given-names>KM</given-names></name><name><surname>Mandla</surname><given-names>R</given-names></name><name><surname>Huerta-Chagoya</surname><given-names>A</given-names></name><name><surname>Melloni</surname><given-names>GEM</given-names></name><name><surname>Kanoni</surname><given-names>S</given-names></name><name><surname>Rayner</surname><given-names>NW</given-names></name><name><surname>Bocher</surname><given-names>O</given-names></name><name><surname>Arruda</surname><given-names>AL</given-names></name><name><surname>Sonehara</surname><given-names>K</given-names></name><name><surname>Namba</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SSK</given-names></name><name><surname>Preuss</surname><given-names>MH</given-names></name><name><surname>Petty</surname><given-names>LE</given-names></name><name><surname>Schroeder</surname><given-names>P</given-names></name><name><surname>Vanderwerff</surname><given-names>B</given-names></name><name><surname>Kals</surname><given-names>M</given-names></name><name><surname>Bragg</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Graff</surname><given-names>M</given-names></name><name><surname>Takeuchi</surname><given-names>F</given-names></name><name><surname>Nano</surname><given-names>J</given-names></name><name><surname>Lamri</surname><given-names>A</given-names></name><name><surname>Nakatochi</surname><given-names>M</given-names></name><name><surname>Moon</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>RA</given-names></name><name><surname>Cook</surname><given-names>JP</given-names></name><name><surname>Lee</surname><given-names>J-J</given-names></name><name><surname>Pan</surname><given-names>I</given-names></name><name><surname>Taliun</surname><given-names>D</given-names></name><name><surname>Parra</surname><given-names>EJ</given-names></name><name><surname>Chai</surname><given-names>J-F</given-names></name><name><surname>Bielak</surname><given-names>LF</given-names></name><name><surname>Tabara</surname><given-names>Y</given-names></name><name><surname>Hai</surname><given-names>Y</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Grarup</surname><given-names>N</given-names></name><name><surname>Sofer</surname><given-names>T</given-names></name><name><surname>Wuttke</surname><given-names>M</given-names></name><name><surname>Sarnowski</surname><given-names>C</given-names></name><name><surname>Gieger</surname><given-names>C</given-names></name><name><surname>Nousome</surname><given-names>D</given-names></name><name><surname>Trompet</surname><given-names>S</given-names></name><name><surname>Kwak</surname><given-names>S-H</given-names></name><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Tong</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W-M</given-names></name><name><surname>Nongmaithem</surname><given-names>SS</given-names></name><name><surname>Noordam</surname><given-names>R</given-names></name><name><surname>Lim</surname><given-names>VJY</given-names></name><name><surname>Tam</surname><given-names>CHT</given-names></name><name><surname>Joo</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>C-H</given-names></name><name><surname>Raffield</surname><given-names>LM</given-names></name><name><surname>Prins</surname><given-names>BP</given-names></name><name><surname>Nicolas</surname><given-names>A</given-names></name><name><surname>Yanek</surname><given-names>LR</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Brody</surname><given-names>JA</given-names></name><name><surname>Kabagambe</surname><given-names>E</given-names></name><name><surname>An</surname><given-names>P</given-names></name><name><surname>Xiang</surname><given-names>AH</given-names></name><name><surname>Choi</surname><given-names>HS</given-names></name><name><surname>Cade</surname><given-names>BE</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Broadaway</surname><given-names>KA</given-names></name><name><surname>Williamson</surname><given-names>A</given-names></name><name><surname>Kamali</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Thangam</surname><given-names>M</given-names></name><name><surname>Adair</surname><given-names>LS</given-names></name><name><surname>Adeyemo</surname><given-names>A</given-names></name><name><surname>Aguilar-Salinas</surname><given-names>CA</given-names></name><name><surname>Ahluwalia</surname><given-names>TS</given-names></name><name><surname>Anand</surname><given-names>SS</given-names></name><name><surname>Bertoni</surname><given-names>A</given-names></name><name><surname>Bork-Jensen</surname><given-names>J</given-names></name><name><surname>Brandslund</surname><given-names>I</given-names></name><name><surname>Buchanan</surname><given-names>TA</given-names></name><name><surname>Burant</surname><given-names>CF</given-names></name><name><surname>Butterworth</surname><given-names>AS</given-names></name><name><surname>Canouil</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>JCN</given-names></name><name><surname>Chang</surname><given-names>L-C</given-names></name><name><surname>Chee</surname><given-names>M-L</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S-H</given-names></name><name><surname>Chen</surname><given-names>Y-T</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Chuang</surname><given-names>L-M</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Das</surname><given-names>SK</given-names></name><name><surname>de Silva</surname><given-names>HJ</given-names></name><name><surname>Dedoussis</surname><given-names>G</given-names></name><name><surname>Dimitrov</surname><given-names>L</given-names></name><name><surname>Doumatey</surname><given-names>AP</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Eckardt</surname><given-names>K-U</given-names></name><name><surname>Emery</surname><given-names>LS</given-names></name><name><surname>Evans</surname><given-names>DS</given-names></name><name><surname>Evans</surname><given-names>MK</given-names></name><name><surname>Fischer</surname><given-names>K</given-names></name><name><surname>Floyd</surname><given-names>JS</given-names></name><name><surname>Ford</surname><given-names>I</given-names></name><name><surname>Franco</surname><given-names>OH</given-names></name><name><surname>Frayling</surname><given-names>TM</given-names></name><name><surname>Freedman</surname><given-names>BI</given-names></name><name><surname>Genter</surname><given-names>P</given-names></name><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Giedraitis</surname><given-names>V</given-names></name><name><surname>González-Villalpando</surname><given-names>C</given-names></name><name><surname>González-Villalpando</surname><given-names>ME</given-names></name><name><surname>Gordon-Larsen</surname><given-names>P</given-names></name><name><surname>Gross</surname><given-names>M</given-names></name><name><surname>Guare</surname><given-names>LA</given-names></name><name><surname>Hackinger</surname><given-names>S</given-names></name><name><surname>Hakaste</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>Herder</surname><given-names>C</given-names></name><name><surname>Horikoshi</surname><given-names>M</given-names></name><name><surname>Howard</surname><given-names>A-G</given-names></name><name><surname>Hsueh</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Hung</surname><given-names>Y-J</given-names></name><name><surname>Hwang</surname><given-names>MY</given-names></name><name><surname>Hwu</surname><given-names>C-M</given-names></name><name><surname>Ichihara</surname><given-names>S</given-names></name><name><surname>Ikram</surname><given-names>MA</given-names></name><name><surname>Ingelsson</surname><given-names>M</given-names></name><name><surname>Islam</surname><given-names>MT</given-names></name><name><surname>Isono</surname><given-names>M</given-names></name><name><surname>Jang</surname><given-names>H-M</given-names></name><name><surname>Jasmine</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Jonas</surname><given-names>JB</given-names></name><name><surname>Jørgensen</surname><given-names>T</given-names></name><name><surname>Kamanu</surname><given-names>FK</given-names></name><name><surname>Kandeel</surname><given-names>FR</given-names></name><name><surname>Kasturiratne</surname><given-names>A</given-names></name><name><surname>Katsuya</surname><given-names>T</given-names></name><name><surname>Kaur</surname><given-names>V</given-names></name><name><surname>Kawaguchi</surname><given-names>T</given-names></name><name><surname>Keaton</surname><given-names>JM</given-names></name><name><surname>Kho</surname><given-names>AN</given-names></name><name><surname>Khor</surname><given-names>C-C</given-names></name><name><surname>Kibriya</surname><given-names>MG</given-names></name><name><surname>Kim</surname><given-names>D-H</given-names></name><name><surname>Kronenberg</surname><given-names>F</given-names></name><name><surname>Kuusisto</surname><given-names>J</given-names></name><name><surname>Läll</surname><given-names>K</given-names></name><name><surname>Lange</surname><given-names>LA</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>M-S</given-names></name><name><surname>Lee</surname><given-names>NR</given-names></name><name><surname>Leong</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li-Gao</surname><given-names>R</given-names></name><name><surname>Ligthart</surname><given-names>S</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Linneberg</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>C-T</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Locke</surname><given-names>AE</given-names></name><name><surname>Louie</surname><given-names>T</given-names></name><name><surname>Luan</surname><given-names>J</given-names></name><name><surname>Luk</surname><given-names>AO</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Lynch</surname><given-names>JA</given-names></name><name><surname>Lyssenko</surname><given-names>V</given-names></name><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Mamakou</surname><given-names>V</given-names></name><name><surname>Mansuri</surname><given-names>SR</given-names></name><name><surname>Matsuda</surname><given-names>K</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Melander</surname><given-names>O</given-names></name><name><surname>Metspalu</surname><given-names>A</given-names></name><name><surname>Mo</surname><given-names>H</given-names></name><name><surname>Morris</surname><given-names>AD</given-names></name><name><surname>Moura</surname><given-names>FA</given-names></name><name><surname>Nadler</surname><given-names>JL</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Nayak</surname><given-names>U</given-names></name><name><surname>Ntalla</surname><given-names>I</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Orozco</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>SR</given-names></name><name><surname>Patil</surname><given-names>S</given-names></name><name><surname>Pei</surname><given-names>P</given-names></name><name><surname>Pereira</surname><given-names>MA</given-names></name><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Pirie</surname><given-names>FJ</given-names></name><name><surname>Polikowsky</surname><given-names>HG</given-names></name><name><surname>Porneala</surname><given-names>B</given-names></name><name><surname>Prasad</surname><given-names>G</given-names></name><name><surname>Rasmussen-Torvik</surname><given-names>LJ</given-names></name><name><surname>Reiner</surname><given-names>AP</given-names></name><name><surname>Roden</surname><given-names>M</given-names></name><name><surname>Rohde</surname><given-names>R</given-names></name><name><surname>Roll</surname><given-names>K</given-names></name><name><surname>Sabanayagam</surname><given-names>C</given-names></name><name><surname>Sandow</surname><given-names>K</given-names></name><name><surname>Sankareswaran</surname><given-names>A</given-names></name><name><surname>Sattar</surname><given-names>N</given-names></name><name><surname>Schönherr</surname><given-names>S</given-names></name><name><surname>Shahriar</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>DM</given-names></name><name><surname>Shojima</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>JA</given-names></name><name><surname>So</surname><given-names>WY</given-names></name><name><surname>Stančáková</surname><given-names>A</given-names></name><name><surname>Steinthorsdottir</surname><given-names>V</given-names></name><name><surname>Stilp</surname><given-names>AM</given-names></name><name><surname>Strauch</surname><given-names>K</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Thorand</surname><given-names>B</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Tomlinson</surname><given-names>B</given-names></name><name><surname>Tran</surname><given-names>TC</given-names></name><name><surname>Tsai</surname><given-names>F-J</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Tusie-Luna</surname><given-names>T</given-names></name><name><surname>Udler</surname><given-names>MS</given-names></name><name><surname>Valladares-Salgado</surname><given-names>A</given-names></name><name><surname>van Dam</surname><given-names>RM</given-names></name><name><surname>van Klinken</surname><given-names>JB</given-names></name><name><surname>Varma</surname><given-names>R</given-names></name><name><surname>Wacher-Rodarte</surname><given-names>N</given-names></name><name><surname>Wheeler</surname><given-names>E</given-names></name><name><surname>Wickremasinghe</surname><given-names>AR</given-names></name><name><surname>van Dijk</surname><given-names>KW</given-names></name><name><surname>Witte</surname><given-names>DR</given-names></name><name><surname>Yajnik</surname><given-names>CS</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Yoon</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Yuan</surname><given-names>J-M</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Zawistowski</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><collab>VA Million Veteran Program</collab><name><surname>Raffel</surname><given-names>LJ</given-names></name><name><surname>Igase</surname><given-names>M</given-names></name><name><surname>Ipp</surname><given-names>E</given-names></name><name><surname>Redline</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>YS</given-names></name><name><surname>Lind</surname><given-names>L</given-names></name><name><surname>Province</surname><given-names>MA</given-names></name><name><surname>Fornage</surname><given-names>M</given-names></name><name><surname>Hanis</surname><given-names>CL</given-names></name><name><surname>Ingelsson</surname><given-names>E</given-names></name><name><surname>Zonderman</surname><given-names>AB</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Wang</surname><given-names>Y-X</given-names></name><name><surname>Rotimi</surname><given-names>CN</given-names></name><name><surname>Becker</surname><given-names>DM</given-names></name><name><surname>Matsuda</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yokota</surname><given-names>M</given-names></name><name><surname>Kardia</surname><given-names>SLR</given-names></name><name><surname>Peyser</surname><given-names>PA</given-names></name><name><surname>Pankow</surname><given-names>JS</given-names></name><name><surname>Engert</surname><given-names>JC</given-names></name><name><surname>Bonnefond</surname><given-names>A</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Sheu</surname><given-names>WHH</given-names></name><name><surname>Wu</surname><given-names>J-Y</given-names></name><name><surname>Hayes</surname><given-names>MG</given-names></name><name><surname>Ma</surname><given-names>RCW</given-names></name><name><surname>Wong</surname><given-names>T-Y</given-names></name><name><surname>Mook-Kanamori</surname><given-names>DO</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name><name><surname>Chandak</surname><given-names>GR</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Bharadwaj</surname><given-names>D</given-names></name><name><surname>Paré</surname><given-names>G</given-names></name><name><surname>Sale</surname><given-names>MM</given-names></name><name><surname>Ahsan</surname><given-names>H</given-names></name><name><surname>Motala</surname><given-names>AA</given-names></name><name><surname>Shu</surname><given-names>X-O</given-names></name><name><surname>Park</surname><given-names>K-S</given-names></name><name><surname>Jukema</surname><given-names>JW</given-names></name><name><surname>Cruz</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y-DI</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>McKean-Cowdin</surname><given-names>R</given-names></name><name><surname>Grallert</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>C-Y</given-names></name><name><surname>Ghanbari</surname><given-names>M</given-names></name><name><surname>Tai</surname><given-names>E-S</given-names></name><name><surname>Dupuis</surname><given-names>J</given-names></name><name><surname>Kato</surname><given-names>N</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Köttgen</surname><given-names>A</given-names></name><name><surname>Koh</surname><given-names>W-P</given-names></name><name><surname>Bowden</surname><given-names>DW</given-names></name><name><surname>Palmer</surname><given-names>CNA</given-names></name><name><surname>Kooner</surname><given-names>JS</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>North</surname><given-names>KE</given-names></name><name><surname>Saleheen</surname><given-names>D</given-names></name><name><surname>Hansen</surname><given-names>T</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>B-J</given-names></name><name><surname>Millwood</surname><given-names>IY</given-names></name><name><surname>Walters</surname><given-names>RG</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Ahlqvist</surname><given-names>E</given-names></name><name><surname>Goodarzi</surname><given-names>MO</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Langenberg</surname><given-names>C</given-names></name><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Loos</surname><given-names>RJF</given-names></name><name><surname>Florez</surname><given-names>JC</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Ritchie</surname><given-names>MD</given-names></name><name><surname>Zöllner</surname><given-names>S</given-names></name><name><surname>Mägi</surname><given-names>R</given-names></name><name><surname>Marston</surname><given-names>NA</given-names></name><name><surname>Ruff</surname><given-names>CT</given-names></name><name><surname>van Heel</surname><given-names>DA</given-names></name><name><surname>Finer</surname><given-names>S</given-names></name><name><surname>Denny</surname><given-names>JC</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Chambers</surname><given-names>JC</given-names></name><name><surname>Ng</surname><given-names>MCY</given-names></name><name><surname>Sim</surname><given-names>X</given-names></name><name><surname>Below</surname><given-names>JE</given-names></name><name><surname>Tsao</surname><given-names>PS</given-names></name><name><surname>Chang</surname><given-names>K-M</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Mahajan</surname><given-names>A</given-names></name><name><surname>Spracklen</surname><given-names>CN</given-names></name><name><surname>Mercader</surname><given-names>JM</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Vujkovic</surname><given-names>M</given-names></name><name><surname>Voight</surname><given-names>BF</given-names></name><name><surname>Morris</surname><given-names>AP</given-names></name><name><surname>Zeggini</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Genetic drivers of heterogeneity in type 2 diabetes pathophysiology</article-title><source>Nature</source><volume>627</volume><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07019-6</pub-id><pub-id pub-id-type="pmid">38374256</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Koso</surname><given-names>H</given-names></name><name><surname>Rust</surname><given-names>AG</given-names></name><name><surname>Yew</surname><given-names>CCK</given-names></name><name><surname>Mann</surname><given-names>MB</given-names></name><name><surname>Ward</surname><given-names>JM</given-names></name><name><surname>Adams</surname><given-names>DJ</given-names></name><name><surname>Copeland</surname><given-names>NG</given-names></name><name><surname>Jenkins</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression</article-title><source>Nature Genetics</source><volume>47</volume><fpage>142</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/ng.3175</pub-id><pub-id pub-id-type="pmid">25559195</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Wyckoff</surname><given-names>GJ</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A universal evolutionary index for amino acid changes</article-title><source>Molecular Biology and Evolution</source><volume>21</volume><fpage>1548</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1093/molbev/msh158</pub-id><pub-id pub-id-type="pmid">15140949</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tate</surname><given-names>JG</given-names></name><name><surname>Bamford</surname><given-names>S</given-names></name><name><surname>Jubb</surname><given-names>HC</given-names></name><name><surname>Sondka</surname><given-names>Z</given-names></name><name><surname>Beare</surname><given-names>DM</given-names></name><name><surname>Bindal</surname><given-names>N</given-names></name><name><surname>Boutselakis</surname><given-names>H</given-names></name><name><surname>Cole</surname><given-names>CG</given-names></name><name><surname>Creatore</surname><given-names>C</given-names></name><name><surname>Dawson</surname><given-names>E</given-names></name><name><surname>Fish</surname><given-names>P</given-names></name><name><surname>Harsha</surname><given-names>B</given-names></name><name><surname>Hathaway</surname><given-names>C</given-names></name><name><surname>Jupe</surname><given-names>SC</given-names></name><name><surname>Kok</surname><given-names>CY</given-names></name><name><surname>Noble</surname><given-names>K</given-names></name><name><surname>Ponting</surname><given-names>L</given-names></name><name><surname>Ramshaw</surname><given-names>CC</given-names></name><name><surname>Rye</surname><given-names>CE</given-names></name><name><surname>Speedy</surname><given-names>HE</given-names></name><name><surname>Stefancsik</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>SL</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Forbes</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>COSMIC: the catalogue of somatic mutations in cancer</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D941</fpage><lpage>D947</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1015</pub-id><pub-id pub-id-type="pmid">30371878</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallejo-Díaz</surname><given-names>J</given-names></name><name><surname>Chagoyen</surname><given-names>M</given-names></name><name><surname>Olazabal-Morán</surname><given-names>M</given-names></name><name><surname>González-García</surname><given-names>A</given-names></name><name><surname>Carrera</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The opposing roles of PIK3R1/p85α and PIK3R2/p85β in cancer</article-title><source>Trends in Cancer</source><volume>5</volume><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2019.02.009</pub-id><pub-id pub-id-type="pmid">30961830</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names><suffix>Jr</suffix></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cancer genome landscapes</article-title><source>Science</source><volume>339</volume><fpage>1546</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1126/science.1235122</pub-id><pub-id pub-id-type="pmid">23539594</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vujkovic</surname><given-names>M</given-names></name><name><surname>Keaton</surname><given-names>JM</given-names></name><name><surname>Lynch</surname><given-names>JA</given-names></name><name><surname>Miller</surname><given-names>DR</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Tcheandjieu</surname><given-names>C</given-names></name><name><surname>Huffman</surname><given-names>JE</given-names></name><name><surname>Assimes</surname><given-names>TL</given-names></name><name><surname>Lorenz</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Hilliard</surname><given-names>AT</given-names></name><name><surname>Judy</surname><given-names>RL</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Klarin</surname><given-names>D</given-names></name><name><surname>Pyarajan</surname><given-names>S</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Melander</surname><given-names>O</given-names></name><name><surname>Rasheed</surname><given-names>A</given-names></name><name><surname>Mallick</surname><given-names>NH</given-names></name><name><surname>Hameed</surname><given-names>S</given-names></name><name><surname>Qureshi</surname><given-names>IH</given-names></name><name><surname>Afzal</surname><given-names>MN</given-names></name><name><surname>Malik</surname><given-names>U</given-names></name><name><surname>Jalal</surname><given-names>A</given-names></name><name><surname>Abbas</surname><given-names>S</given-names></name><name><surname>Sheng</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name><name><surname>Susztak</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>YV</given-names></name><name><surname>DuVall</surname><given-names>SL</given-names></name><name><surname>Cho</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Gaziano</surname><given-names>JM</given-names></name><name><surname>Phillips</surname><given-names>LS</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Reaven</surname><given-names>PD</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Edwards</surname><given-names>TL</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Damrauer</surname><given-names>SM</given-names></name><name><surname>O’Donnell</surname><given-names>CJ</given-names></name><name><surname>Tsao</surname><given-names>PS</given-names></name><collab>HPAP Consortium</collab><collab>Regeneron Genetics Center</collab><collab>VA Million Veteran Program</collab><name><surname>Chang</surname><given-names>K-M</given-names></name><name><surname>Voight</surname><given-names>BF</given-names></name><name><surname>Saleheen</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis</article-title><source>Nature Genetics</source><volume>52</volume><fpage>680</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-0637-y</pub-id><pub-id pub-id-type="pmid">32541925</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waarts</surname><given-names>MR</given-names></name><name><surname>Stonestrom</surname><given-names>AJ</given-names></name><name><surname>Park</surname><given-names>YC</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Targeting mutations in cancer</article-title><source>The Journal of Clinical Investigation</source><volume>132</volume><elocation-id>e154943</elocation-id><pub-id pub-id-type="doi">10.1172/JCI154943</pub-id><pub-id pub-id-type="pmid">35426374</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Shao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>C</given-names></name><name><surname>Duke</surname><given-names>NC</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Extensive gene flow in secondary sympatry after allopatric speciation</article-title><source>National Science Review</source><volume>9</volume><elocation-id>wac280</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwac280</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Collisson</surname><given-names>EA</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Shaw</surname><given-names>KRM</given-names></name><name><surname>Ozenberger</surname><given-names>BA</given-names></name><name><surname>Ellrott</surname><given-names>K</given-names></name><name><surname>Shmulevich</surname><given-names>I</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The cancer genome atlas pan-cancer analysis project</article-title><source>Nature Genetics</source><volume>45</volume><fpage>1113</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1038/ng.2764</pub-id><pub-id pub-id-type="pmid">24071849</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CI</given-names></name><name><surname>Ting</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Genes and speciation</article-title><source>Nature Reviews. Genetics</source><volume>5</volume><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1038/nrg1269</pub-id><pub-id pub-id-type="pmid">14735122</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CI</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Ling</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The ecology and evolution of cancer: the ultra-microevolutionary process</article-title><source>Annual Review of Genetics</source><volume>50</volume><fpage>347</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-112414-054842</pub-id><pub-id pub-id-type="pmid">27686281</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C-I</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>What are species and how are they formed?</article-title><source>National Science Review</source><volume>9</volume><elocation-id>nwad017</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwad017</pub-id><pub-id pub-id-type="pmid">36788966</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The genetics of race differentiation-should it be studied?</article-title><source>National Science Review</source><volume>10</volume><elocation-id>wad068</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwad068</pub-id><pub-id pub-id-type="pmid">37034147</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>D</given-names></name><name><surname>Narisu</surname><given-names>N</given-names></name><name><surname>Taylor</surname><given-names>DL</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Grenko</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>HJ</given-names></name><name><surname>Yan</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Sinha</surname><given-names>N</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Vandana</surname><given-names>JJ</given-names></name><name><surname>Nok Chong</surname><given-names>AC</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Mansell</surname><given-names>EC</given-names></name><name><surname>Swift</surname><given-names>AJ</given-names></name><name><surname>Erdos</surname><given-names>MR</given-names></name><name><surname>Zhong</surname><given-names>A</given-names></name><name><surname>Bonnycastle</surname><given-names>LL</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Functional interrogation of twenty type 2 diabetes-associated genes using isogenic human embryonic stem cell-derived β-like cells</article-title><source>Cell Metabolism</source><volume>35</volume><fpage>1897</fpage><lpage>1914</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2023.09.013</pub-id><pub-id pub-id-type="pmid">37858332</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Swanson</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Codon-substitution models to detect adaptive evolution that account for heterogeneous selective pressures among site classes</article-title><source>Molecular Biology and Evolution</source><volume>19</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.molbev.a003981</pub-id><pub-id pub-id-type="pmid">11752189</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Ro</surname><given-names>S</given-names></name><name><surname>Rannala</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Likelihood models of somatic mutation and codon substitution in cancer genes</article-title><source>Genetics</source><volume>165</volume><fpage>695</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1093/genetics/165.2.695</pub-id><pub-id pub-id-type="pmid">14573481</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>W</given-names></name><name><surname>Lai</surname><given-names>H</given-names></name><name><surname>Kaya</surname><given-names>NA</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Lim</surname><given-names>JQ</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Chew</surname><given-names>SC</given-names></name><name><surname>Chua</surname><given-names>KP</given-names></name><name><surname>Alvarez</surname><given-names>JJS</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Chang</surname><given-names>MM</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Goh</surname><given-names>BKP</given-names></name><name><surname>Chung</surname><given-names>AY-F</given-names></name><name><surname>Chan</surname><given-names>CY</given-names></name><name><surname>Cheow</surname><given-names>PC</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Kam</surname><given-names>JH</given-names></name><name><surname>Kow</surname><given-names>AW-C</given-names></name><name><surname>Ganpathi</surname><given-names>IS</given-names></name><name><surname>Chanwat</surname><given-names>R</given-names></name><name><surname>Thammasiri</surname><given-names>J</given-names></name><name><surname>Yoong</surname><given-names>BK</given-names></name><name><surname>Ong</surname><given-names>DB-L</given-names></name><name><surname>de Villa</surname><given-names>VH</given-names></name><name><surname>Dela Cruz</surname><given-names>RD</given-names></name><name><surname>Loh</surname><given-names>TJ</given-names></name><name><surname>Wan</surname><given-names>WK</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Skanderup</surname><given-names>AJ</given-names></name><name><surname>Pang</surname><given-names>YH</given-names></name><name><surname>Madhavan</surname><given-names>K</given-names></name><name><surname>Lim</surname><given-names>TK-H</given-names></name><name><surname>Bonney</surname><given-names>G</given-names></name><name><surname>Leow</surname><given-names>WQ</given-names></name><name><surname>Chew</surname><given-names>V</given-names></name><name><surname>Dan</surname><given-names>YY</given-names></name><name><surname>Tam</surname><given-names>WL</given-names></name><name><surname>Toh</surname><given-names>HC</given-names></name><name><surname>Foo</surname><given-names>RS-Y</given-names></name><name><surname>Chow</surname><given-names>PK-H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study</article-title><source>National Science Review</source><volume>9</volume><elocation-id>wab192</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwab192</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>CDN_V1</data-title><version designator="swh:1:rev:967361fff2b70ae2a39360e5546c18710dc3700f">swh:1:rev:967361fff2b70ae2a39360e5546c18710dc3700f</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:537fa75d5dbe96ca6724820877ba5255b2d9cac3;origin=https://gitlab.com/ultramicroevo/cdn_v1;visit=swh:1:snp:f4700c8f857c51a5745c5f3ef4b6c6dbddc3b4c0;anchor=swh:1:rev:967361fff2b70ae2a39360e5546c18710dc3700f">https://archive.softwareheritage.org/swh:1:dir:537fa75d5dbe96ca6724820877ba5255b2d9cac3;origin=https://gitlab.com/ultramicroevo/cdn_v1;visit=swh:1:snp:f4700c8f857c51a5745c5f3ef4b6c6dbddc3b4c0;anchor=swh:1:rev:967361fff2b70ae2a39360e5546c18710dc3700f</ext-link></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>T</given-names></name><name><surname>Liufu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs)</article-title><source>eLife</source><volume>13</volume><elocation-id>e99340</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.99340</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>N</given-names></name><name><surname>Suo</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Proteomics of adjacent-to-tumor samples uncovers clinically relevant biological events in hepatocellular carcinoma</article-title><source>National Science Review</source><volume>10</volume><elocation-id>wad167</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwad167</pub-id><pub-id pub-id-type="pmid">37575948</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>The overlap of cancer drivers from IntOGen, Bailey et al. and CGC Tier 1 (<xref ref-type="bibr" rid="bib5">Bailey et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Sondka et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Martínez-Jiménez et al., 2020</xref>).</title><p>Driver genes (dots) for 12 cancer types were extracted from each driver list, indicated by three different region colors. The area size of each region is proportional to the gene number, with 384 genes for IntOGen, 168 for Bailey et al. and 137 for CGC Tier 1. Genes with a significant positive selection signal in the merged mutation set are marked in red, while nonsignificant ones are colored in blue. Notably, genes shared across the three driver sets are largely those with a significant Ka/Ks &gt; 1.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99341-app1-fig1-v1.tif"/></fig></app><app id="appendix-2"><title>Appendix 2</title><sec sec-type="appendix" id="s8"><title>1. Quantifying evolutionary fitness of CDN</title><p>We leverage Eqs. 2 and 4 from the companion paper (<xref ref-type="bibr" rid="bib69">Zhang et al., 2024</xref>) and rewrite <bold><italic>A<sub>i</sub></italic></bold> as follows:<disp-formula id="equ6"><label>(S4)</label><mml:math id="m6"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msubsup></mml:math></disp-formula></p><p>where <bold><italic>A<sub>i</sub></italic></bold> represents the observed site number with missense recurrence of <italic>i</italic>, which could be further decomposed into two components: <inline-formula><mml:math id="inf28"><mml:msubsup><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>, the site number with missense recurrence of <italic>i</italic> under neutral mutational force, and <inline-formula><mml:math id="inf29"><mml:msubsup><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>, which occurs under positive selection. For <inline-formula><mml:math id="inf30"><mml:msubsup><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>, we have<disp-formula id="equ7"><label>(S5)</label><mml:math id="m7"><mml:msubsup><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mi>f</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>g</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:mfenced><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>w</mml:mi><mml:mo>⋅</mml:mo><mml:mi>n</mml:mi><mml:mi>E</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula></p><p>With <xref ref-type="disp-formula" rid="equ6 equ7">Equations S4 and S5</xref>, <bold><italic>A<sub>i</sub></italic></bold> could be expressed as<disp-formula id="equ8"><label>(S6)</label><mml:math id="m8"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Γ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Γ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi mathvariant="normal">Γ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>k</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>⋅</mml:mo><mml:mfrac><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>k</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msup></mml:mfrac><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>u</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msup><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>f</mml:mi><mml:mo>⋅</mml:mo><mml:msup><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>2.3</mml:mn><mml:mo>⋅</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>f</mml:mi><mml:mo>⋅</mml:mo><mml:msup><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <italic>f</italic> denotes the fraction of missense sites under positive selection (<italic>f</italic> ≪ 1), and <bold><italic>w</italic></bold> represents the selective advantage (<italic>s</italic>) scaled by the population size of progenitor cancer cell (<italic>N</italic>). First, we aimed to estimate <italic>f</italic> from the discrepancy between <inline-formula><mml:math id="inf31"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf32"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>. The number of sites under positive selection in <bold><italic>A<sub>1</sub></italic></bold> (<inline-formula><mml:math id="inf33"><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">*</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>) could be approximated from <bold><italic>A<sub>0</sub></italic></bold> as <inline-formula><mml:math id="inf34"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>f</mml:mi></mml:math></inline-formula>, which could also be derived from the excess of mutations from <bold><italic>A<sub>1</sub></italic></bold> as <inline-formula><mml:math id="inf35"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, then we have<disp-formula id="equ9"><mml:math id="m9"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>f</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></disp-formula><disp-formula id="equ10"><label>(S7)</label><mml:math id="m10"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>f</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>Based on the average statistics in <xref ref-type="table" rid="table1">Table 1</xref>, <italic>f</italic> could be estimated from <xref ref-type="disp-formula" rid="equ8">Equation S6</xref> to be 3.13 × 10<sup>–4</sup>. With synonymous recurrence sites as neutral reference, <inline-formula><mml:math id="inf36"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mn>2.3</mml:mn><mml:mo>⋅</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>f</mml:mi><mml:mo>⋅</mml:mo><mml:msup><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfenced></mml:math></inline-formula>. Given <bold><italic>A<sub>3</sub></italic></bold>/<bold><italic>S<sub>3</sub></italic></bold> = 5.25, we will have <bold><italic>w</italic></bold> = 16, which means <bold><italic>A<sub>3</sub></italic></bold> would be 4096 (16<sup>3</sup>) fold higher than the neutral expectation.</p></sec><sec sec-type="appendix" id="s9"><title>2. Functional annotation of new cancer drivers</title><p>A limitation in cancer driver discovery lies in the modeling of background mutation process, which often necessitates a balance between current knowledge and unknown mutational mechanisms. Consequently, genes recognized as canonical drivers in one cancer type may be categorized as noncanonical in others due to the lack of statistical significance. Of the 229 noncanonical drivers identified across six cancer types, 19 genes have been previously recognized as canonical drivers in different cancer types, while 23 genes were classified as drivers in IntOGen through a combination of diverse statistical methods.</p><p>For the newly identified noncanonical CDN genes in this study, we explore their potential functional relevance to cancer through a two-step procedure. First, we annotate these genes considering gene ontology, pathway, disease association, and protein–protein interaction with known cancer drivers. Subsequently, we conduct manual curation by reviewing published literatures for evidence related to cancer. <xref ref-type="fig" rid="app2fig1">Appendix 2—figure 1</xref> illustrates how noncanonical CDGs are enriched in cancer-related biological processes in lung and colon cancers. The results reveal that processes such as cell migration/adhesion, epithelial-to-mesenchymal transition (EMT), cell proliferation, energy metabolism, immune response, and DNA transcription activity are among the most enriched processes in both cancer types. Additionally, other cancer hallmark-related processes, such as the cell cycle control, DNA stability, and response to stresses, are also enriched among noncanonical CDN genes.</p><p>In <xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2</xref>, we present the top 10 genes being most connected to known cancer drivers across four independent enrichment analyses. Here, we take two unidentified driver genes for example to illustrate their functional roles relating to cancer. <italic>PIK3R2</italic> (phosphoinositide-3-kinase regulatory subunit 2), which encodes p85β of class I PI3K, is often highly expressed in most tumors (<xref ref-type="bibr" rid="bib31">Liu et al., 2022</xref>). This gene has a CDN mutation of G1117A (with amino acid change of G373R) in endometrium cancer, which is also presented in lung and urinary tract cancers. <italic>PIK3R2</italic> has been reported as an oncogene, with its overexpression triggering cell transformation in culture and promoting cancer progression in mouse model (<xref ref-type="bibr" rid="bib54">Vallejo-Díaz et al., 2019</xref>). <italic>SLC7A5</italic> (solute carrier family 7 member 5), with a CDN mutation of G1480A (V494I) in colon cancer, plays a critical oncogenic role in maintaining intracellular amino acid levels for an elevated protein synthesis rate in <italic>KRAS</italic>-mutant cells. Depletion of <italic>SLC7A5</italic> suppresses intestinal tumorigenesis in mice and resensitizes tumors to protein synthesis inhibition (<xref ref-type="bibr" rid="bib36">Najumudeen et al., 2021</xref>). In conclusion, although excluded from the canonical driver list due to the lack of statistical significance, noncanonical CDN genes may still undergo positive selection at the site level. Ongoing research may provide further experimental evidence for these genes as part of an ongoing effort to identify the complete set of cancer drivers.</p><fig id="app2fig1" position="float"><label>Appendix 2—figure 1.</label><caption><title>Noncanonical cancer driver genes (CDGs) in colon and lung cancer along with associated biological processes (Y-axis).</title><p>For each gene, we examine its annotation results from GO analysis and search for cancer-related evidence in the literature. Biological processes are summarized and curated in relation to cancer hallmarks. Each connection between gene ID and biological process is depicted by a blue block in the grid.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99341-app2-fig1-v1.tif"/></fig><fig id="app2fig2" position="float"><label>Appendix 2—figure 2.</label><caption><title>Top 10 noncanonical cancer driver genes (CDGs) with the highest enrichment records with IntOGen’s driver list from four enrichment analysis.</title><p>Panels (<bold>A–D</bold>) corresponds to Gene Ontology, KEGG, Disease Ontology, and Reactome analysis, respectively. The X-axis represents the number of enrichment records for each gene, while genes are listed on the Y-axis according to their enrichment record number. Genes with different occurrences across the top set of four analysis are marked with red (three hits), blue (two hits) and black (one hit).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99341-app2-fig2-v1.tif"/></fig></sec><sec sec-type="appendix" id="s10"><title>3. The specificity of CDNs in cancer detection</title><p>Generally, in a given sample, each mutated gene would harbor one mutation. Therefore, we measure the false-positive rate for CDNs (or CDGs) as the proportion of individuals harboring nonsynonymous mutations at CDN (or CDGs). Across 487 individuals from noncancerous set, 446 are devoid of any mutations at CDNs, yielding a specificity of 91.6% (false-positive rate: 8.4%). In contrast, for CDGs downloaded from CGC, the specificity is 37.6% (false-positive rate: 62.4%). The high specificity implies the potential application of CDNs in biopsy and companion diagnostics, as well as the possibility of integration with other early screening pipelines. Furthermore, when we compared the mutations of recurrences <italic>i</italic> ≥ 3 in <italic>SomaMutDB</italic> with CDNs identified in our analysis, no overlap was observed. The high exclusiveness of CDNs between cancer and noncancer implies that positive selection operates in a specific manner in cancer, distinct from normal tissues.</p></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99341.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Weigel</surname><given-names>Detlef</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Max Planck Institute for Biology Tübingen</institution><country>Germany</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This <bold>valuable</bold> study is a companion to a paper introducing a theoretical framework and methodology for identifying cancer-driving nucleotides (CDNs). The evidence that recurrent SNVs or CDNs are common in true cancer driver genes is <bold>convincing</bold>, with more limited evidence that many more undiscovered cancer driver mutations will have CDNs, and that this approach could identify these undiscovered driver genes with about 100,000 samples.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99341.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The study investigates Cancer Driving Nucleotides (CDNs) using the TCGA database, finding that these recurring point mutations could greatly enhance our understanding of cancer genomics and improve personalized treatment strategies. Despite identifying 50-150 CDNs per cancer type, the research reveals that a significant number remain undiscovered, limiting current therapeutic applications, underscoring the need for further larger-scale research.</p><p>Strengths:</p><p>The study provides a detailed examination of cancer-driving mutations at the nucleotide level, offering a more precise understanding than traditional gene-level analyses. The authors found a significant number of CDNs remain undiscovered, with only 0-2 identified per patient out of an expected 5-8, indicating that many important mutations are still missing. The study indicated that identifying more CDNs could potentially significantly impact the development of personalized cancer therapies, improving patient outcomes.</p><p>Weaknesses:</p><p>The challenges in direct functional testing of CDNs due to the complexity of tumor evolution and unknown mutation combinations limit the practical applicability of the findings.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99341.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The study proposes that many cancer driver mutations are not yet identified but could be identified if they harbor recurrent SNVs. The paper leverages the analysis from Paper #1 that used quantitative analysis to demonstrate that SNVs or CDNs seen 3 or more times are more likely due to selection (ie a driver mutation) than by chance or random mutation.</p><p>Strengths:</p><p>Empirically, mutation frequency is an excellent marker of a driver gene because canonical driver mutations typically have recurrent SNVs. Using the TCGA database, the paper illustrates that CDNs can identify canonical driver mutations (Fig 3) and that most CDN are likely to disrupt protein function (Fig 2). In addition, CDNs can be shared between cancer types (Fig 4).</p><p>Weaknesses:</p><p>Driver alteration validation is difficult, with disagreements on what defines a driver mutation, and how many driver mutations are present in a cancer. The value proposed by the authors is that the identification of all driver genes can facilitate the design of patient specific targeting therapies, but most targeted therapies are already directed towards known driver genes. There is an incomplete discussion of oncogenes (where activating mutations tend to target a single amino acid or repeat) and tumor suppressor genes (where inactivating mutations may be more spread across the gene). Other alterations (epigenetic, indels, translocations, CNVs) would be missed by this type of analysis.</p><p>The method could be more valuable when applied to the noncoding genome, where driver mutations in promoters or enhancers are relatively rare, or as yet to be discovered. Increasingly more cancers have had whole genome sequencing. Compared to WES, criteria for driver mutations in noncoding regions are less clear, and this method could potentially provide new noncoding driver CDNs. Observing the same mutation in more than one cancer specimen is empirically unusual, and the authors provide a solid quantitative analysis that indicates many recurrent mutations are likely to be cancer-driver mutations.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99341.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lingjie</given-names></name><role specific-use="author">Author</role><aff><institution>Sun Yat-sen University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Tong</given-names></name><role specific-use="author">Author</role><aff><institution>Sun Yat-sen University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liufu</surname><given-names>Zhongqi</given-names></name><role specific-use="author">Author</role><aff><institution>Kunming Institute of Zoology</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiangnyu</given-names></name><role specific-use="author">Author</role><aff><institution>Sun Yat-sen University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Shijie</given-names></name><role specific-use="author">Author</role><aff><institution>Sun Yat-sen University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xueyu</given-names></name><role specific-use="author">Author</role><aff><institution>Sun Yat-sen University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Changhao</given-names></name><role specific-use="author">Author</role><aff><institution>Sun Yat-sen University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Bingjie</given-names></name><role specific-use="author">Author</role><aff><institution>Guangzhou Medical University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Zheng</given-names></name><role specific-use="author">Author</role><aff><institution>Shenzhen Institute of Advanced Technology</institution><addr-line><named-content content-type="city">Shenzhen</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Qichun</given-names></name><role specific-use="author">Author</role><aff><institution>Jinan University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Chenli</given-names></name><role specific-use="author">Author</role><aff><institution>Shenzhen Institute of Advanced Technology</institution><addr-line><named-content content-type="city">Shenzhen</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Mengfeng</given-names></name><role specific-use="author">Author</role><aff><institution>Southern Medical University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Tracy</surname><given-names>Miles E</given-names></name><role specific-use="author">Author</role><aff><institution>Sun Yat-sen University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Xuemei</given-names></name><role specific-use="author">Author</role><aff><institution>Kunming Institute of Zoology</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Chung-I</given-names></name><role specific-use="author">Author</role><aff><institution>University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Hai-Jun</given-names></name><role specific-use="author">Author</role><aff><institution>Sun Yat-sen University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>eLife Assessment</bold></p><p>This valuable study is a companion to a paper introducing a theoretical framework and methodology for identifying Cancer Driving Nucleotides (CDNs). While the evidence that recurrent SNVs or CDNs are common in true cancer driver genes is solid, the evidence that many more undiscovered cancer driver mutations will have CDNs, and that this approach could identify these undiscovered driver genes with about 100,000 samples, is limited.</p><p>Same criticism as in the eLife assessment of eLife-RP-RA-2024-99340 (<ext-link ext-link-type="uri" xlink:href="https://elifesciences.org/reviewed-preprints/99340">https://elifesciences.org/reviewed-preprints/99340</ext-link>). Hence, please refer to the responses to the companion paper.</p><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>The study investigates Cancer Driving Nucleotides (CDNs) using the TCGA database, finding that these recurring point mutations could greatly enhance our understanding of cancer genomics and improve personalized treatment strategies. Despite identifying 50-150 CDNs per cancer type, the research reveals that a significant number remain undiscovered, limiting current therapeutic applications, and underscoring the need for further larger-scale research.</p><p>Strengths:</p><p>The study provides a detailed examination of cancer-driving mutations at the nucleotide level, offering a more precise understanding than traditional gene-level analyses. The authors found a significant number of CDNs remain undiscovered, with only 0-2 identified per patient out of an expected 5-8, indicating that many important mutations are still missing. The study indicated that identifying more CDNs could potentially significantly impact the development of personalized cancer therapies, improving patient outcomes.</p><p>Weaknesses:</p><p>The study is constrained by relatively small sample sizes for each cancer type, which reduces the statistical power and robustness of the findings. ICGC and other large-scale WGS datasets are publicly available but were not included in this study.</p></disp-quote><p>Thanks. We indeed have used all public data, including GENIE (figure 7 of the companion paper), ICGC and other integrated resources such as COSMIC. The main study is based on TCGA because it is unbiased for estimating the probability of CDN occurrences. In many datasets, the numerators are given but the denominators are not (the number of patients with the mutation / the total number of patients surveyed). In GENIE, we observed that E(u) estimated upon given sequencing panels are much smaller than in TCGA, this might be due to the selective report of nonsynonymous mutations for synonymous mutations are generally considered irrelevant in tumorigenesis.</p><disp-quote content-type="editor-comment"><p>To be able to identify rare driver mutations, more samples are needed to improve the statistical power, which is well-known in cancer research. The challenges in direct functional testing of CDNs due to the complexity of tumor evolution and unknown mutation combinations limit the practical applicability of the findings.</p></disp-quote><p>We fully agree. We now add a few sentences, making clear that the theory allows us to see how much more can be gained by each stepwise increase in sample size. For example, when the sample size reaches 106, further increases will yield almost no gain in confidence of CDNs identified see figures of eLife-RP-RA-2024-99340. As pointed out in our provisional responses, an important strength of this pair of studies is that the results are testable. The complexity is the combination of mutations required for tumorigenesis and the identification of such combinations is the main goal and strength of this pair of studies. We add a few sentences to this effect.</p><p>While the importance of large sample sizes in identifying cancer drivers is well-recognized, the analytical framework presented in the companion paper (<ext-link ext-link-type="uri" xlink:href="https://elifesciences.org/reviewed-preprints/99340">https://elifesciences.org/reviewed-preprints/99340</ext-link>) goes a step further by quantitatively elucidating the relationship between sample size and the resolution of CDN detection.</p><p>The question is very general as it is about multigene interactions, or epistasis. The challenges are true in all aspects of evolutionary biology, for example, the genetics of reproductive isolation(Wu and Ting 2004). The issue of epistasis is difficult because most, if not all, of the underlying mutations have to be identified in order to carry out functional tests. While the full identification is rarely feasible, it is precisely the objective of the CDN project. When the sample size increases to 100,000 for a cancer type, all point mutations for that cancer type should be identifiable.</p><disp-quote content-type="editor-comment"><p>The QC of the TCGA data was not very strict, i.e, &quot;patients with more than 3000 coding region point mutations were filtered out as potential hypermutator phenotypes&quot;, it would be better to remove patients beyond +/- 3*S.D from the mean number of mutations for each cancer type. Given some point mutations with &gt;3 hits in the TCGA dataset, they were just false positive mutation callings, particularly in the large repeat regions in the human genome.</p></disp-quote><p>Thanks. The GDC data portal offers data calls from multiple pipelines, enabling us to select mutations detected by at least two pipelines. While including patients with hypermutator phenotypes could introduce potential noise, as shown in Eq. 10 of the main text, our method for defining the upper limit of i* is relative robust to the fluctuations in the E(u) of the corresponding cancer population. Since readers may often ask about this, we expand the Methods section somewhat to emphasize this point.</p><disp-quote content-type="editor-comment"><p>The codes for the statistical calculation (i.e., calculation of Ai_e, et al) are not publicly available, which makes the findings hard to be replicated.</p></disp-quote><p>We have now updated the section of “Data Availability” in both papers. The key scripts for generating the major results are available at: <ext-link ext-link-type="uri" xlink:href="https://gitlab.com/ultramicroevo/cdn_v1">https://gitlab.com/ultramicroevo/cdn_v1</ext-link>.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>The study proposes that many cancer driver mutations are not yet identified but could be identified if they harbor recurrent SNVs. The paper leverages the analysis from Paper #1 that used quantitative analysis to demonstrate that SNVs or CDNs seen 3 or more times are more likely to occur due to selection (ie a driver mutation) than they are to occur by chance or random mutation.</p><p>Strengths:</p><p>Empirically, mutation frequency is an excellent marker of a driver gene because canonical driver mutations typically have recurrent SNVs. Using the TCGA database, the paper illustrates that CDNs can identify canonical driver mutations (Figure 3) and that most CDNs are likely to disrupt protein function (Figure 2). In addition, CDNs can be shared between cancer types (Figure 4).</p><p>Weaknesses:</p><p>Driver alteration validation is difficult, with disagreements on what defines a driver mutation, and how many driver mutations are present in a cancer. The value proposed by the authors is that the identification of all driver genes can facilitate the design of patient-specific targeting therapies, but most targeted therapies are already directed towards known driver genes. There is an incomplete discussion of oncogenes (where activating mutations tend to target a single amino acid or repeat) and tumor suppressor genes (where inactivating mutations may be more spread across the gene). Other alterations (epigenetic, indels, translocations, CNVs) would be missed by this type of analysis.</p></disp-quote><p>The above paragraph has three distinct points. We shall respond one by one.</p><p>First, … <italic>can facilitate the design of patient-specific targeting therapies, but most targeted therapies are already directed towards known driver genes…</italic></p><p>We state in the text of Discussion the following that shows only a few best-known driving mutations have been targeted. It is accurate to say that &lt; 5% of CDNs we have identified are on the current targeting list. Furthermore, this list we have compiled is &lt; 10% of what we expect to find.</p><p>Direct functional test of CDNs would be to introduce putative cancer-driving mutations and observe the evolution of tumors. Such a task of introducing multiple mutations that are collectively needed to drive tumorigenesis has been done only recently, and only for the best-known cancer driving mutations (Ortmann et al. 2015; Takeda et al. 2015; Hodis et al. 2022). In most tumors, the correct combination of mutations needed is not known. Clearly, CDNs, with their strong tumorigenic strength, are suitable candidates.</p><p>Second, “There is an incomplete discussion of oncogenes (where activating mutations tend to target a single amino acid or repeat) and tumor suppressor genes (where inactivating mutations may be more spread across the gene).”</p><p>We sincerely thank the reviewer for this insightful comment. Below are two new paragraphs in the Discussion pertaining to the point:</p><p>In this context, we should comment on the feasibility of targeting CDNs that may occur in either oncogenes (ONCs) or tumor suppressor genes (TSGs). It is generally accepted that ONCs drive tumorigenesis thanks to the gain-of-function (GOF) mutations whereas TSGs derive their tumorigenic powers by loss-of-function (LOF) mutations. It is worthwhile to point out that, since LOF mutations are likely to be more widespread on a gene, CDNs are biased toward GOF mutations. The often even distribution of non-sense mutations along the length of TSGs provide such evidence. As gene targeting aims to diminish gene functions, GOF mutations are perceived to be targetable whereas LOF mutations are not. By extension, ONCs should be targetable but TSGs are not. This last assertion is not true because mutations on TSGs may often be of the GOF kind as well.</p><p>The data often suggest that mis-sense mutations on TSGs are of the GOF kind. If mis-sense mutations are far more prevalent than nonsense mutations in tumors, the mis-sense mutations cannot possibly be LOF mutations. (After all, it is not possible to lose <italic>more</italic> functions than nonsense mutations.) For example, AAA to AAC (K to Q) is a mis-sense mutation while AAA to AAT (K to stop) is a non-sense mutation. In a separate study (referred to as the escape-route analysis), we found many cases where the mis-sense mutations on TSGs are more prevalent (&gt; 10X) than nonsense mutations. Another well-known example is the distribution of non-sense mutations TSGs. For example, on <italic>APC</italic>, a prominent TSG, non-sense mutations are far more common in the middle 20% of the gene than the rest (Zhang and Shay 2017; Erazo-Oliveras et al. 2023). The pattern suggests that even these non-sense mutations could have GOF properties.</p><p>The following response is about the clinical implications of our CDN analysis. Canonical targeted therapy often relies on the Tyrosine Kinase Inhibitors (TKIs) (Dang et al. 2017; Danesi et al. 2021; Waarts et al. 2022). Theoretically, any intervention that suppresses the expression of gain-of-function (GOF) CDNs could potentially have therapeutic value in cancer treatment. This leads us to a discussion of oncogenes versus TSGs in the context of GOF / LOF (loss of function) mutations. Not all mutations on oncogenes have oncogenic effect, besides, truncated mutations in oncogenes are often subject to negative selection (Bányai et al. 2021), the identification of CDNs within oncogenes is therefore crucial for developing effective cancer treatment guidelines. Secondly, while TSGs are generally believed to promote cancer development via loss of function mutations, research suggests that certain mutations within TSGs can have GOF-like effect, such as the dominant negative effect of truncated TP53 mutations (Marutani et al. 1999; de Vries et al. 2002; Gerasimavicius et al. 2022). Characterizing driver mutations as GOF or LOF mutations could potentially expand the scope of targeted cancer therapy. We’ll address this issue in a third study in preparation.</p><disp-quote content-type="editor-comment"><p>The method could be more valuable when applied to the noncoding genome, where driver mutations in promoters or enhancers are relatively rare, or as yet to be discovered. Increasingly more cancers have had whole genome sequencing. Compared to WES, criteria for driver mutations in noncoding regions are less clear, and this method could potentially provide new noncoding driver CDNs. Observing the same mutation in more than one cancer specimen is empirically unusual, and the authors provide a solid quantitative analysis that indicates many recurrent mutations are likely to be cancer-driver mutations.</p></disp-quote><p>Again, we are grateful for the comments which prompt us to expand a paragraph in Discussion, reproduced below.</p><p>The CDN approach has two additional applications. First, it can be used to find CDNs in non-coding regions. Although the number of whole genome sequences at present is still insufficient for systematic CDN detection, the preliminary analysis suggests that the density of CDNs in non-coding regions is orders of magnitude lower than in coding regions. Second, CDNs can also be used in cancer screening with the advantage of efficiency as the targeted mutations are fewer. For the same reason, the false negative rate should be much lower too. Indeed, the false positive rate should be far lower than the gene-based screen which often shows a false positive rate of &gt;50% (supplement File S1).</p><p>Again, we are grateful that Reviewer #2 have addressed the potential value of our study in finding cancer drivers in non-coding regions. A major challenge in this area lies in defining the appropriate <italic>L</italic> value as presented in Eq. 10. In the main text, we used a gamma distribution to account for the variability of mutation rates across sites in coding region. For the non-coding region, we will categorize these regions based on biological annotations. The goal is to set different <italic>i*</italic> cutoffs for different genomic regions (such as heterochromatin / euchromatin, GC-rich regions or centromeric regions), and avoid false positive calls for CDN in repeated regions (Elliott and Larsson 2021; Peña et al. 2023).</p><p>References</p><p>Bányai L, Trexler M, Kerekes K, Csuka O, Patthy L. 2021. Use of signals of positive and negative selection to distinguish cancer genes and passenger genes. <italic>Elife</italic> 10:e59629.</p><p>Danesi R, Fogli S, Indraccolo S, Del Re M, Dei Tos AP, Leoncini L, Antonuzzo L, Bonanno L, Guarneri V, Pierini A, et al. 2021. Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. <italic>ESMO Open</italic> 6:100040.</p><p>Dang CV, Reddy EP, Shokat KM, Soucek L. 2017. Drugging the “undruggable” cancer targets. <italic>Nat Rev Cancer</italic> 17:502–508.</p><p>Elliott K, Larsson E. 2021. Non-coding driver mutations in human cancer. <italic>Nat Rev Cancer</italic> 21:500–509.</p><p>Erazo-Oliveras A, Muñoz-Vega M, Mlih M, Thiriveedi V, Salinas ML, Rivera-Rodríguez JM, Kim E, Wright RC, Wang X, Landrock KK, et al. 2023. Mutant APC reshapes Wnt signaling plasma membrane nanodomains by altering cholesterol levels via oncogenic β-catenin. <italic>Nat Commun</italic> 14:4342.</p><p>Gerasimavicius L, Livesey BJ, Marsh JA. 2022. Loss-of-function, gain-of-function and dominant-negative mutations have profoundly different effects on protein structure. <italic>Nat Commun</italic> 13:3895.</p><p>Hodis E, Triglia ET, Kwon JYH, Biancalani T, Zakka LR, Parkar S, Hütter J-C, Buffoni L, Delorey TM, Phillips D, et al. 2022. Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment. <italic>Science</italic> 376:eabi8175.</p><p>Marutani M, Tonoki H, Tada M, Takahashi M, Kashiwazaki H, Hida Y, Hamada J, Asaka M, Moriuchi T. 1999. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. <italic>Cancer Res</italic> 59:4765–4769.</p><p>Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, et al. 2015. Effect of Mutation Order on Myeloproliferative Neoplasms. <italic>N Engl J Med</italic> 372:601–612.</p><p>Peña MV de la, Summanen PAM, Liukkonen M, Kronholm I. 2023. Chromatin structure influences rate and spectrum of spontaneous mutations in <italic>Neurospora crassa</italic>. <italic>Genome Res.</italic> 33:599–611.</p><p>Takeda H, Wei Z, Koso H, Rust AG, Yew CCK, Mann MB, Ward JM, Adams DJ, Copeland NG, Jenkins NA. 2015. Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression. <italic>Nat Genet</italic> 47:142–150.</p><p>de Vries A, Flores ER, Miranda B, Hsieh H-M, van Oostrom CThM, Sage J, Jacks T. 2002. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. <italic>Proceedings of the National Academy of Sciences</italic> 99:2948–2953.</p><p>Waarts MR, Stonestrom AJ, Park YC, Levine RL. 2022. Targeting mutations in cancer. <italic>J Clin Invest</italic> 132:e154943.</p><p>Wu C-I, Ting C-T. 2004. Genes and speciation. <italic>Nat Rev Genet</italic> 5:114–122.</p><p>Zhang L, Shay JW. 2017. Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer. <italic>JNCI: Journal of the National Cancer Institute</italic> 109:djw332.</p></body></sub-article></article>